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ABSTRACT 
Pharmaceutical compounds comprise a wide range of substances that are 
consumed in large quantities by modern societies and are generally released 
into local sewer networks through excretion. This research aimed to identify the 
factors affecting the removal efficiencies of these compounds in biological 
wastewater treatment plants (WWTPs) under different environmental 
conditions. Of the pharmaceutical compounds selected for this study, the 
highest influent concentrations measured in municipal wastewater treatment 
plants (MWWTPs) were for paracetamol, naproxen and bezafibrate (> 1 µg/L), 
followed by carbamazepine, atenolol, lidocaine, sulfamethoxazole and NACS (< 
1 µg/L). In hospital wastewater treatment plants (HWWTPs), the highest 
concentrations measured were for paracetamol and caffeine (> 10 µg/L), 
followed by ciprofloxacin and NACS (1–6 µg/L), and finally bezafibrate, 
carbamazepine, atenolol, lidocaine, clarithromycin and sulfamethoxazole (< 1 
µg/L). Antibiotic drugs were detected in HWWTPs, but rarely detected in 
MWWTPs. In general, the hospital wastewaters contained relatively higher 
levels of pharmaceuticals than municipal wastewaters. 
The removal efficiencies of the pharmaceutical compounds ranged widely. This 
was found to be related to characteristics and operational parameters of the 
individual WWTPs. The MWWTPs that utilized long aeration and biomass 
retention times (HRT,SRT), as evidenced by the occurrence of complete 
nitrification, were more efficient at removing paracetamol, naproxen, bezafibrate 
and atenolol, than the non-nitrifying plants with relatively shorter HRT and SRT. 
HWWTPs that operated under elevated ambient temperatures (> 26°C) 
achieved higher removal efficiencies (90%) for several compounds, including 
paracetamol, caffeine, sulfamethoxazole, ciprofloxacin, clarithromycin, NACS, 
atenolol, carbamazepine and lidocaine. In addition to the elevated ambient 
temperatures, elevated HRT and SRT and less dilution can lead to increased 
active biomass and can result in higher removal rates for the pharmaceutical 
compounds. Overall, the removal efficiencies of pharmaceuticals in WWTPs 
have been correlated to the type of treatment plant, the plants’ operational 
parameters (HRT, SRT), the climatic conditions (temperature and dilution effect 
of rainfall) and characteristics of the micropollutants (type and concentration). 
Aerobic and anaerobic batch biodegradation experiments were conducted to 
observe the removal of paracetamol, naproxen, ibuprofen and sulfamethoxazole 
at various SRTs. The biodegradation rates varied widely ranging from poor, to 
moderate, to high, depending on the SRT. Paracetamol was highly 
biodegradable under both aerobic and anaerobic conditions. Sulfamethoxazole 
was poorly biodegradable under aerobic conditions but highly biodegradable 
under anaerobic conditions. Relatively slow biodegradation rates were observed 
for ibuprofen and naproxen under both conditions; longer microbial adaptation 
periods for these two compounds were probably required. The most important 
factor affecting the removal of the compounds was the SRT. Therefore, the 
conclusion was drawn that combining anaerobic and aerobic systems with 
longer SRT and HRT could bring about signiﬁcant reductions in the emissions 
of these contaminants into the environment via WWTPs; this is also a cost-
effective option. 
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CHAPTER 1 
General introduction 
1.1 Background 
Municipal wastewater (MWW) consists of wastewater from households, 
manufacturing industries and commercial enterprises, and rainwater run-off 
from roads and other impermeable surfaces (such as roofs and pavements) that 
drain into sewers (Defra 2012). Untreated wastewater can cause signiﬁcant 
damage to the environment. Therefore, different types of wastewater treatment 
have been designed to remove various contaminants. The treatment of 
wastewater aims to remove pollutants including pathogens, organic compounds 
and nutrients. In many countries, MWW and other wastewaters, like hospital 
wastewater (HWW), are treated together, in centralised sewage treatment 
plants. 
For many years, organic pollutants in surface waters have mainly been 
measured by analysing the biochemical oxygen demand (BOD), chemical 
oxygen demand (COD) and total suspended solids (SS) (Cirja et al. 2008). 
However, during the 1970s and 1980s, researchers reported the presence of 
organic micropollutants, such as human hormones and pharmaceutical 
compounds, in surface waters (Tabak and Bunch 1970; Tabak, et al. 1981). 
Pharmaceutical compounds, which are consumed in large quantities within 
modern societies, have since been detected in several different environmental 
compartments (wastewaters, rivers, lakes, groundwaters, and sediments, etc.) 
around the world and continue to increase in concentration.  
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Although there are several different pathways by which human pharmaceutical 
compounds are discharged into the environment, municipal wastewater 
treatment plants (WWTPs) are by far the most important source (Figure 1.1).  
 
 
Fig. 1.1: Exposure routes of human pharmaceutical compounds into 
wastewater and the aquatic environment. 
 
 
Conventional WWTPs are known to effectively treat carbon, nitrogen and 
microbial pollutants (macropollutants). However, they also receive a wide 
variety of micropollutants that may pass through the treatment plant into surface 
waters without being significantly reduced during treatment. This is due, 
generally, to the low concentrations of pharmaceutical compounds in effluent 
and the fact that WWTPs are not normally designed to remove these types of 
pollutants. Consequently, the continuous input of pharmaceutical compounds 
and their metabolites into the environment from WWTPs, even at low 
concentrations, could cause long-term environmental effects and could even 
affect public health via drinking water. The overall release of these compounds 
and the effects that they may cause are not fully understood. One exception is 
endocrine disrupting compounds, which have been extensively assessed and 
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are known to have negative effects on aquatic organisms. Thus, environmental 
contamination by pharmaceutical compounds is a worldwide problem that may 
continue to grow as the potential for pharmaceutical compounds to cause long-
term damage within ecosystems begins to be better understood. Public 
awareness and concern about pharmaceutical compounds in the environment 
has grown significantly, and has brought the issue to the forefront of water 
quality management. In particular, there has been an increasing amount of 
research focusing on risk assessment, aimed at evaluating the effects of these 
substances in the ecosystems, in light of the increasing consumption of 
pharmaceutical compounds in modern societies. The European Union has 
recently taken action, by monitoring micropollutants through several projects 
that are aimed at quantifying their removal rates during standard and advanced 
wastewater treatment processes, and their presence in receiving waters. 
Notable examples of these studies include:  
 
 PILLS project (Pharmaceuticals Input and Elimination from Local 
Sources, 2007–2012). The PILLS project aims (i) to identify which 
treatment methods are best suited to reduce pharmaceutical residues 
and antibiotic resistant bacteria in wastewater, (ii) to gain more 
knowledge about the circumstances under which local treatment, for 
example at hospitals, is reasonable  and (iii ) to increase awareness of 
this problem across Europe (PILLS project 2012).  
 
 BIOTREAT (Bio-treatment of drinking water resources polluted by 
pesticides, pharmaceuticals and other micropollutants). BIOTREAT is a 
 4 
 
European Union (EU) project initiated on 1 January 2011 aiming to 
develop new technologies for bioremediation of drinking water resources 
contaminated with micropollutants, such as pesticides and 
pharmaceuticals (Biotreat 2013). 
 
 “Measures to reduce the input of micropollutants into water bodies” 
(2012–2014). The purpose of this project was to develop appropriate 
measures to reduce the input of micropollutants discharged by the 
municipal wastewater treatment plants and sewer systems into water 
bodies (KIT 2013). 
In addition, the European Union has taken legislative action on micropollutants, 
with Directive 2013/39/EU of the European Parliament and of the Council 
(European Commission 2014), in order to minimise the risks to the environment.  
 
1.2 Aim of this research 
The overall aim of this research was to identify the factors affecting the removal 
efficiencies of pharmaceutical compounds in biological WWTPs under different 
environmental conditions, in order to propose guidelines for their reduction in 
the aquatic environment.  
 
 1.3 Objectives 
The objectives of the research include the following: 
 Identify a common point source of pharmaceutical compounds in MWWs. 
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 Identify the important pharmaceutical compounds that are released by 
the point source.  
 Identify the factors that affect the removal efficiency of those 
pharmaceutical compounds under different environmental conditions. 
 Assess the fate of pharmaceuticals during different biological treatment 
systems. 
 Recommend feasible methodologies for the treatment of common human 
pharmaceutical compounds under various climatic conditions. 
 
Two main field studies were carried out at WWTPs in Saudi Arabia and the UK 
and an additional laboratory study was conducted (biodegradation experiments) 
to address the objectives of the research.  
 
1.4 Organisation 
This thesis is divided into eight chapters, including this introduction and the 
conclusions. Furthermore, each chapter is subdivided into further subsections. 
This chapter (Chapter 1) has presented an overview of the issue that this 
research aims to address and the organisation of this work.  
Chapter 2 consists of a literature review of HWWs, identified to be the main 
point source of pharmaceutical compounds in MWWs. The chapter includes an 
analysis of the sources of HWW, characterisation of HWW (the consumption of 
water and pharmaceutical compounds in hospitals) and the known fates of 
pharmaceutical compounds during different wastewater treatment processes. 
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The differences between macropollutants and micropollutants in wastewater are 
also discussed.   
In Chapter 3 the methodologies employed for the research are presented. This 
includes the rationale for selecting (i) the pharmaceutical compounds to monitor 
in the WWTPs, and (ii) the locations and types of WWTPs. In addition, details of 
the sampling and analysis methods for the wastewaters are provided. The 
methodologies used in laboratory biodegradation experiments have also been 
included in this chapter.  
Chapter 4 reviews the current hospital wastewater management practices in 
the UK and Saudi Arabia, the countries used as case studies in this research. 
The review presents the collection, treatment and disposal of hospital 
wastewaters in these countries.  
Chapter 5 presents and discusses the results of the field studies conducted at 
different wastewater treatment plants across the UK and Saudi Arabia. These 
studies investigated the average concentrations of conventional pollutants and 
pharmaceutical compounds in the selected wastewater treatment plants. The 
potential influence of the operational parameters on removal efficiencies is 
discussed.  
Chapter 6 presents the results of the laboratory biodegradation experiments, 
which consider the potential biodegradation of selected pharmaceutical 
compounds under aerobic and anaerobic conditions, in order to assess and 
discuss the fate of pharmaceuticals under these important conditions.  
Chapter 7 proposes management practices for pharmaceutical compounds in 
WWTPs, in tropical and temperate climates. Finally, Chapter 8 presents the 
general conclusions of this research and recommendations for future research. 
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CHAPTER 2 
Pharmaceuticals in hospital wastewater 
 Sources, characterisation and fate 
 
2.1 Introduction  
Pharmaceutical compounds constitute a wide group of compounds that are 
largely used for the treatment of health conditions and protection of humans and 
other animals from disease. When they are released into the aquatic 
ecosystems, they may have an adverse effect on the organisms inhabiting 
those ecosystems. These pollutants, in general, originate from urban 
environments, are collected in wastewater collection systems and may finally 
reach the aquatic natural environment in discharged effluent. Until recently, 
these compounds have not been of a major concern with regard to their 
environmental effects. 
Studies have shown that hospitals are a major point source of pharmaceutical 
compounds to wastewater treated in wastewater treatment plants (WWTPs) 
(Helwig et al. 2013). Hospital wastewater (HWW) contains various hazardous 
and toxic materials, such as microbiological pathogens (e.g. antibiotic resistant 
bacteria and viruses), hazardous chemical compounds, disinfectants, 
pharmaceutical compounds, and radioactive isotopes, among others (Pauwels 
and Verstraete 2006; Verlicchi et al. 2010a; Verlicchi et al. 2012b: Permatasari 
and Mangkoedihardjo 2012). HWW is generally connected to urban sewer 
systems, so municipal wastewaters (MWW) and HWW are usually co-treated in 
conventional WWTPs (Alder et al. 2006). This is where the problem really 
begins, as municipal wastewater treatment plants are not designed to remove 
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medical or pharmaceuticals waste. The scientific community recommends the 
pre-treatment of HWWs, to enhance the degradation of micropollutants (Altin et 
al. 2003; Pauwels and Verstraete 2006), before discharge into municipal 
wastewater collection and treatment systems. Hospital management strategies 
have therefore become a subject of lively discussion in the scientific community, 
which has recently started to evaluate the contributions of HWWs to MWWs, in 
terms of the micropollutant loads at local point sources (WWTPs) into the 
environment (Verlicchi et al. 2012b). 
 
2.2 Water consumption in hospitals 
Hospitals are amongst the largest water consumers in a community. They 
require significant amounts of water for various uses and applications. Hospitals 
typically consume water at between 500 and 1200 L/bed/day (Emmanuel et al. 
2005). The water consumption of an individual hospital depends on several 
factors, including number of beds, hospital age, accessibility to water, general 
services present inside the hospital (e.g., kitchen, laundry and air conditioning) 
and the number of wards and units (Verlicchi et al. 2010a,b). In addition, the 
institution’s management policies and awareness in managing the hospital and 
safeguarding the environment, climate, cultural and geographical factors are 
important (Verlicchi et al. 2010a, b). 
Water consumption varies from country to country, during different seasons, 
and even during the day. For example, the average water consumption in the 
USA and France is 968 and 750 L/bed/day, respectively; for developing 
countries it is just 500 L/bed/day (Emmanuel et al. 2005). In terms of the effect 
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of season, higher average consumption values were observed during the 
summer time in multiple studies (Joss et al. 2005; Mohee 2005; Boillot et al. 
2008). During the day, flow rates are increased up to 20% above average 
between 8 a.m. and 4 p.m., and are 30% below average between 1 a.m. and 8 
a.m. (Verlicchi et al. 2010a). Sanitation consumes the most water out of the 
major hospital services, according to an analysis of seven European hospitals, 
ranging from 130 to 500 beds, with water consumption rates between 56 and 
549 million L/year (Figure 2.1) (ESC 2013).  
 
Fig. 2.1: Water consumption in hospitals (ESC 2013) 
 
The consumption of water in hospitals is expected to increase as a result of the 
development of medical services and health care products. Alongside this 
increase in the consumption of water, hospitals are expected to generate 
increasingly significant amounts of wastewater. Mesdaghinia et al. (2009) 
compared the average water consumption per bed with the average wastewater 
production in eight hospitals and their results indicated that 75–85% of the total 
fresh water consumed in hospitals becomes wastewater (Figure 2.2).  
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Fig. 2.2: The average water consumption and wastewater production per bed in 
eight hospitals located in Iran (Mesdaghinia et al. 2009) 
 
2.3 Pharmaceutical consumption and hospital contribution  
The consumption of pharmaceutical compounds has increased significantly 
since the 1950s due to factors including population growth, the development of 
medical science and the emergence of diseases, particularly infectious 
diseases (Le Corre et al. 2012). The consumption rate of common 
pharmaceutical compounds (antidiabetics and antidepressants) has continued 
to increase during the last decade in several countries (Figure 2.3) (OECD 
2014). Country-wide data on the consumption of pharmaceutical compounds in 
hospitals, especially for inpatients, remains limited. Helwig et al. (2013) reported 
the consumption of selected pharmaceutical compounds in hospitals across 
different European countries, in terms of the annual totals of the prescribed 
medicine at each hospital (Table 2.1).  
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Fig. 2.3: The consumption of antidiabetics and antidepressants in 2000 and 
2011 for different countries (OECD 2014). 
 
Table 2.1: The average annual consumption of selected pharmaceutical 
compounds in hospitals across different European countries (Helwig et al. 2013) 
 Hospital pharmaceutical consumption 
(g/bed/year) 
Country1  DE LU FR NL UK2 UK3 
Year 2011 2010 2010 Mean 2011 2011 
No. of beds 560 360 863 1076 265 318 
Diclofenac 7.07 1.62 1.93 0.50 3.26 3.98 
Naproxen 0.00 8.73 2.18 0.07 3.98 1.85 
Carbamazepine 1.64 1.00 2.91 0.00 4.34 4.49 
Atenolol 0.27 0.15 0.64 0.00 2.20 1.59 
Bezafibrate 0.84 0.00 0.00 0.01 0.78 0.41 
Lidocaine 0.00 2.21 46.95 2.36 17.21 8.45 
Amoxicillin 22.73 92.52 67.05 47.49 72.26 125.37 
Ciprofloxacin 9.61 16.50 21.80 8.96 27.31 24.19 
Clarithromycin 3.82 5.47 0.85 0.40 24.75 18.04 
Sulfamethoxazole 3.32 0.33 13.39 5.37 0.00 15.07 
Erythromycin 2.18 0.55 2.93 1.45 2.12 2.41 
Diatrizoate 67.06 0.00 181.37 3.89 0.00 29.45 
Iopamidol 13.49 0.00 4.36 0.00 687.67 9.63 
Iopromide 0.00 0.00 0 248.42 4.26 0.00 
Cyclophosphamide 0.31 0.48 1.79 1.94 0.00 8.45 
Ifosfamide 0.10 0.28 0.71 0.03 0.18 0.00 
1DE (Germany), LU (Luxemburg), FR (France), NL (the Netherlands) and UK 
(Scotland); 2Rural UK hospital; 3Urban UK hospital. 
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The investigation by Helwig et al. (2013) indicated that consumption (by weight) 
of the pharmaceutical compounds was highest for contrast media (for single 
compounds up to 981 g/bed/annum), while generally there were also relatively 
high consumption figures for antibiotics (typically 5–25 g/bed/annum).  
Vogler et al. (2010) indicated that the most commonly consumed drugs in 
European hospitals are paracetamol, furosemide, acetylsalicylic acid, epoetin 
beta and albumin. Table 2.2 shows the share percentages of the total volume of 
selected drugs that were used in hospitals in Germany, in 1998 and 2001, and 
demonstrates that all of the contrast media and cytostatic drugs examined, as 
well as ampicillin, penicillin G and vancomycin (of the antibiotics examined), 
were mainly administered in hospitals (Alder et al. 2006). Antibiotic groups are 
among the most common drugs consumed worldwide. The worldwide antibiotic 
market consumption was previously estimated to be between 100,000 and 
200,000 tons annually, of which approximately 25% was used in hospitals 
(Kümmerer 2003; Wise 2002). The consumption of antibiotics increased by 36% 
between 2000 and 2010 (Van Boeckel et al. 2014).   
Once pharmaceuticals have been administered to patients, the dosages are 
excreted as either parent compounds or metabolites via urine and faeces into 
wastewater treatment plants. However, a significant proportion of drugs 
dispensed in hospitals are issued to patients but not excreted within the hospital 
environment (Helwig et al. 2013). Overall, the consumption and application of 
pharmaceutical compounds in a hospital vary over the year and from country to 
country (Schuster et al. 2008). 
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Table 2.2: Hospital usage of selected drugs as a percentage (%) of total use in 
Germany (Alder et al. 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
The contribution of pharmaceutical compounds from HWWs to the receiving 
WWTPs vary widely, depending on the different groups of pharmaceuticals, and 
from hospital to hospital (Verlicchi et al. 2010a). Helwig et al. (2013) reported 
the concentrations of some antibiotics from different European hospital 
wastewaters compared to MWWTPs to be up to 154% (ciprofloxacin), 59% 
(clarithromycin), 53% (sulfamethoxazole) and 82% (erythromycin) of the 
concentrations found. Another study found that the concentration of 
ciprofloxacin in HWW was 272% higher than the local MWWTP in Norway 
(Thomas et al. 2007). Antibiotic groups are highly toxic to organisms in the 
environment, especially algae and bacteria (Pauwels and Verstraete 2006; 
Watkinso et al. 2009). Some antibiotics, used in hospitals, are designed to 
cause DNA damage to bacteria or eukaryotic cells (Kümmerer et al. 2000). The 
Drugs Compound   1998   2001 
 
Antibiotics Amoxicillin 
Ampicillin 
Ciprofloxacin 
Metronidazol 
Penicillin g 
Sulfamethoxazole 
Vancomycin 
Clarithromycin 
 
12 
82 
34 
38 
93 
13 
92 
9 
11 
86 
31 
50 
94 
12 
94 
13 
Contrast  
media 
Diatriaoate 
Iomeprol 
Iopamidol 
Iopromide 
 
98 
100 
96 
100 
98 
100 
97 
100 
Cytostatic Cyclophosphamide 
Ifosfamide 
67 
95 
67 
97 
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concentrations levels of antibiotics in HWWs were reported between 4 and 100 
times greater than their respective concentrations in domestic wastewaters 
(Joss et al. 2006).  
Santos et al. (2013) reported that non-steroidal anti-inflammatory drugs 
(NSAIDs), analgesics and antibiotics were the largest contributors to the total 
load of pharmaceuticals at WWTPs that originated from HWWs, corresponding 
to 51%, 41% and 32%, respectively. Sources of the X-ray contrast agent 
(iopromide and iopamidol) in HWW were found to contribute up to 100% to the 
final WWTP load (Helwig et al. 2013). 
In general, the consumption of pharmaceuticals and relative hospital 
contribution to wastewater vary widely amongst different therapeutic groups, 
hospitals and countries depending on lifestyle, hospital size, legislation, 
economy, types of prevalent diseases and population size (Santos et al. 2013; 
Helwig et al. 2013; Kümmerer and Schuster 2008).  
 
2.4 Disposal of pharmaceutical compounds in hospitals  
Pharmaceutical compounds from hospitals are released into MWWs via two 
main pathways: excretion from patients or through unsuitable disposal (i.e. 
disposed of down sinks or toilets). For the disposal of unwanted drugs, there 
are generally standard procedures that hospitals should use (WHO 2014). 
However, in some instances, abuse of these procedures by hospital staff and/or 
patients occurs during the disposal of unwanted drugs (Kallaos et al. 2007). For 
example, unwanted pharmaceutical compounds may be illegally disposed of 
into the sewage system or as solid waste. Disposal into the sewage system 
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contributes to raising the concentrations of pharmaceutical compounds in 
HWWs and eventually MWWs. Kallaos et al. (2007) investigated the disposal 
methods of unwanted pharmaceuticals in different institutions, including 
hospitals, nursing homes and pharmacies. Their study showed that the disposal 
of unwanted drugs by direct disposal into the drainage system was not a 
common disposal method (Figure 2.4). 
 
 
 
 
 
 
 
 
Fig. 2.4: The average frequency scores of the disposal methods for unwanted 
drugs used in hospitals and nursing homes in Santa Barbara, USA. Trash = solid 
waste; Drain = disposal to drainage system; and frequency scores represent a gradient 
from never (1) to very frequently (5) (Kallaos et al. 2007). 
 
 
2.5 Hospital wastewater sources 
Hospital wastewater contains various hazardous compounds including 
microbiological pathogens, hazardous chemical compounds, disinfectants, 
pharmaceutical compounds and radioactive isotopes, as discussed in Section 
2.1. It is important to understand the sources within hospitals that contribute to 
the generation of hazardous pollutants. If these are known, the hazardous 
and/or toxic compounds in HWW can be predicted and effectively managed at 
their source. An effective HWW management system requires knowledge of the 
source points, and the adverse impacts the compounds have on the aquatic 
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environment. Although it is rather difficult to estimate and classify the units of 
HWW discharged, this section describes the sources of wastewater from 
different hospital units. A previous study reported that HWW comes from three 
essential units of the hospital (Verlicchi et al. 2010a):  
1. General units: such as the laundry, kitchen, and heating and cooling 
systems.  
2. Medical units: such as the laboratories, radiology units and 
haemodialysis units.  
3. Patient ward units: such as general medicine, surgery, specialities, 
haemodialysis, and intensive care, among others.  
The wastewater that comes from these various units differs in both quality and 
quantity. The wastewater that is generated from the laundry and kitchen units is 
generally similar quality to urban wastewater and is classified as domestic 
wastewater (Verlicchi et al. 2010a). The general units usually produce 
approximately 40% of the total HWW and these units do not normally pose 
serious challenges to the treatment processes or include hazardous 
compounds.  
On the other hand, wastewater that comes from medical units and patient wards 
is likely to be loaded with multiple pollutants that are toxic and hazardous. The 
Medical Academic and Scientific Community Organization (MASCO 1996) 
classified the sources of pollutants from hospitals into four categories, three of 
which constitute ‘medical units’ (Table 2.3); each category is a source of 
different types of pollutants.  The major source of pharmaceutical compounds in 
WW is excretion by patients (Jjemba 2006). Patients excrete these compounds 
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via urine or faeces (as discussed in Section 2.4) as parent compounds or 
metabolites (Langford and Thomas 2009).  
 
Table 2.3: Type and source of pollutants from hospital units (MASCO 1996) 
Sources 
 
Pollutants Comparison of BOD5
1 
and COD2 with 
domestic waste water 
Clinical 
laboratory 
Heavy metals, organic chemicals, 
blood products and body fluids, 
phosphates, oil, grease, particulate 
materials, buffers, and dilute mineral 
acids/bases. 
 
BOD5 and COD values 
are higher than domestic 
wastewater values. 
Research 
laboratory 
 
Oxidizers, radio nuclides, proteins, 
oil, grease, heavy metals, organic 
solvents, blood products and body 
fluids, formaldehyde, phosphates, 
detergents, and photographic 
imaging chemicals. 
 
BOD5 and COD values 
are lower than clinical 
laboratory, but above 
average domestic 
wastewater 
Medical 
waste 
incinerators 
 
Low organic materials and oxidizers, 
high particulate materials and heavy 
metals. 
 
BOD5 and COD values 
are lower than domestic 
wastewater  
 
Hospital 
laundry 
Fats, oil, grease, detergents, 
proteins, and oxidizers 
BOD5 and COD values 
are usually in the normal 
range for domestic 
wastewater  
1Biochemical oxygen demand; 2Chemical oxygen demand. 
 
2.6 Characteristics of hospital wastewater 
It is useful to understand the characteristics and quantities of HWW being 
generated, in order to optimise wastewater treatment processes. As already 
noted (Section 2.1), hospital wastewater contains a wide variety of pollutants 
including organic and inorganic pollutants. Usually, organic pollutants in HWWs 
are composed of natural organic matter, soluble microbial products, harmful 
chemicals and by-products that are known as dissolved organic matter 
(>0.45µm) (Shon et al. 2006). These pollutants, either macropollutants or 
 18 
 
micropollutants, play an important role in the composition and classification of 
HWWs. 
 
2.6.1. Macropollutants  
Macropollutants (i.e. conventional pollutants) are quantitatively estimated, 
mainly through the measurement of biochemical oxygen demand (BOD5), 
chemical oxygen demand (COD), suspended solids (SS), and total coliforms, 
among other measures. A comparison of macropollutants between HWWs 
(hospital sizes 60–900 beds) and MWWs showed that macropollutants in 
HWWs are generally higher than in MWWs (Table 2.4) (Verlicchi et al. 2010b). 
In particular, conventional parameters, such as COD and BOD5 were higher; 
these are the most common indicators used to measure the amount of organic 
macropollutants in waste waters. 
 
Table 2.4: Comparison of average concentrations of macropollutants between 
HWW and MWW (Verlicchi et al. 2010b). 
Parameter Unit HWW MWW 
pH - 7.0–9.0 7.5–8.5 
Redox potential mV 850–1000 420–1340 
TKN1 mg/L 5–100 20–70 
Total phosphorus mg/L 0.2–13 4–10 
Fat and oil mg/L 5–60 50–150 
Chlorides mg/L 65–400 30–100 
Total surfactants mg/L 3–7.2 4–8 
Escherichia coli MPN/100mL 103–106 106–107 
Faecal coliforms MPN/100mL 103–107 106–108 
Total coliforms MPN/100mL 105–108 107–1010 
BOD5
2 mg/L 150–603 100–400 
COD3 mg/L 450–2300 500–600 
SS4 mg/L 120–400 120–350 
1Total kjeldahl nitrogen; 2biochemical oxygen demand; 3chemical oxygen demand; 
4susepended solids 
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Several studies have investigated BOD5 and COD concentrations in raw HWWs 
from different countries (Table 2.5); BOD5 values ranged from 100 to 1545 mg/L 
while COD values ranged from 337 to 2590 mg/L. The levels of conventional 
macropollutants in HWWs vary from country to country, and are also related to 
the size of the hospital and the type of services supplied. In general, the 
concentrations of organic macropollutants in HWW are higher than those in 
MWW but do not pose a significantly different challenge compared to MWW in  
wastewater treatment processes. 
 
Table 2.5: The average concentrations of BOD5 and COD (mg/L) in raw 
hospital wastewater from different countries. 
Country BOD5 COD Reference 
Thailand 410 1350 Kajitvichyanukul et al. 2006 
Italy 240 480 Verlicchi et al. 2010a 
Iran 245 592 Sarafraz et al. 2006 
Iran 412 814 Mahvi et al. 2009 
Egypt 210 570 El-Gawad et al. 2011 
Turkey 147 337 Altin et al. 2003 
Iran 444 789 Mesdaghinia 2009 
Greece 348 527 Nasr et al. 2008 
France 1545 2590 Emmanuel et al. 2005 
France 603 855 Emmanuel et al. 2002 
Brazil 100 380 Chagas et al. 2011 
Spain — 490 Cruz-Morato et al. 2014 
 
 
2.6.2. Micropollutants 
Hospital wastewater also contains several varieties of dissolved chemical 
substances (< 0.45 µm), including micropollutants, which are generally present 
at low concentrations (between µg/L and ng/L). These micropollutants are also 
considered to be emerging contaminants and include pharmaceutical 
compounds, hormones, fragrances, disinfectants, halogens, heavy metals and 
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other organic and inorganic compounds (Verlicchi et al. 2012a; Verlicchi et al. 
2010b). Many new pharmaceutical compounds and health care products are 
continuously being introduced into the market, due to new legislation, 
healthcare improvements and the emergence of new diseases. This section 
focuses on pharmaceutical compounds as environmental contaminants. These 
compounds, used largely in healthcare are mainly organic compounds. There 
are many different classes of pharmaceutical compounds that are commonly 
used in hospitals (Table 2.6) (Verlicchi et al. 2010b).  
 
Table 2.6: Main classes of pharmaceutical compounds that are consumed in 
hospitals (Verlicchi et al. 2010b). 
 
 
Class Example 
 
Antibiotics Sulfamethoxazole, ciprofloxacin, coprofloxacin, 
chlortetracycline, erythromycin, doxycycline, 
lincomycin, norfloxacin, ofloxacin, oxytetracycline, 
penicillin, cefazolin,, tetracycline, trimethoprim 
Analgesics and  
anti-inflammatories 
Ibuprofen, naproxen, paracetamol, diclofenac, 
indomethacin, ketoprofen, mefenamic acid, 
propyphenazone, salycilic acid, codeine, dipyrone. 
Cytostatics 5-Fluorouracil, ifosfamide 
Anaesthetics Propofo, lidocainel 
Disinfectants Triclosan, glutaraldehyde 
Iodized contrast 
media (ICM) 
Iopromide, iopamidol 
Psychiatric drugs, 
antidepressants, 
anticonvulsants 
Carbamazepine, gabapentin, phenytoin, 
valproic acid 
Antihistamines Ranitidine, cimetidine 
Antihypertensive Diltiazem 
Antidiabetics Glibenclamide 
B-blockers Atenolol, metroprolol, propranolol, solatolol 
Hormones 17 b-Estradiol, estriol, estrone, ethinylestradiol 
Lipid regulators Atorvastatina, bezafibrate, clofibric acid, 
gemfibrozil, pravastatin 
Diuretics Furosemide, hydrochlorotiazide 
Stimulants 
Heavy metals 
Caffeine 
Platinum, mercury 
Musk and fragrance Tonalide, galoxolide 
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Most of the pharmaceutical compounds in Table 2.6 are administered to 
patients for oral intake or via intravenous application. Either way, they are 
eventually excreted by patients into the sewer system as metabolites or un-
metabolised forms. Some pharmaceutical compounds may be readily 
metabolised, moderately metabolised, poorly metabolised, or remain un-
metabolized after consumption. Parent pharmaceuticals and their metabolites 
differ in both their pharmacological and toxicological properties. Although 
pharmaceutical compounds are usually present in relatively small 
concentrations in wastewater, some of them are more stable than 
macropollutants and cannot be quickly broken down during wastewater 
treatment processes. Therefore, they pose an additional challenge for the 
wastewater treatment processes and can pass into environmental systems, 
where they can cause negative effects (Fent 2008). 
Hospital wastewaters are significant sources of antibiotics, anaesthetics, anti-
cancer drugs, anti-inflammatories, disinfectants, heavy metals, adsorbable 
organic halogens (AOX), contrast media and cytostatic agents (Kümmerer 
2001). For example, in a study of a hospital WWTP in Germany, high 
concentrations of antibiotics (particularly ciprofloxacin and erythromycin) were 
detected in both the influent and effluent (Ohlsen et al. 2003). Further, primary 
DNA damage in bacteria within HWWs was correlated strongly with 
ciprofloxacin concentration (0.7–124.5 μg/L) (Hartmann et al. 1999). This study 
confirmed the growing evidence that active pharmaceutical compounds from 
hospitals, in this case, antibiotics, are being distributed into the aquatic 
environment and have negative effects on organisms. 
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Iodinated contrast media (ICM) are also important pharmaceutical compounds 
within hospitals. The worldwide consumption of ICM was previously measured 
to be approximately 3.5 × 106 kg/year (Perez and Barcelo 2007b). Oleksy-
Frenzel et al. (2000) detected high concentrations, of up to 130 µg/L, of organic 
iodine compounds in MWWTP in Berlin and up to 10 mg/L in a HWW. These 
compounds are not readily biodegradable during conventional wastewater 
treatment processes (Pauwels and Verstraete 2006).  
One major concern regarding the input of pharmaceutical compounds into the 
environment is their genotoxicity. For example, hormonal drugs can disturb the 
hormonal balance and cause hermaphroditism in fish (Purdom 1994). The 
endocrine disrupting residues may not just be a problem for aquatic organisms, 
but may also affect the human population (Casals-Casas & Desvergne 2011; 
Yu et al. 2013). Polluted effluent discharged to freshwater ecosystems can 
eventually reach oceanic ecosystems, potentially endangering marine wildlife; 
thus the pollution problem caused by chemical contaminants in HWWs is a 
global issue. 
 
2.7 Fate of pharmaceuticals in common biological wastewater treatment 
systems 
2.7.1 Activated sludge  
The activated sludge process (ASP) is the most popular biological treatment 
process employed particularly in municipal WWTPs throughout the world.  Many 
ASP plants operate under aerobic condition. The majority of published data  
show a significant variation in the removal efficiencies of pharmaceutical 
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compounds by ASP ranging from high (e.g., paracetamol and ibuprofen) to poor 
(e.g., carbamazepine) (Kim et al. 2005; Alvarez et al. 2002; Marquez et al. 
2011). The significant removal reported refers to biodegradation or sorption on 
solids (Barret et al. 2010). The levels of biodegradation in ASP have been 
reported to be affected by operational parameters (McAdam et al. 2010; Sahar 
et al. 2011) (see Section 2.8). There is evidence that some parameters such as 
solid retention time (SRT), hydraulic retention time (HRT) and temperature 
affect removal efficiencies (Fernandez-Fontaina et al. 2012; Verlicchi et al. 
2012a), which might explain the variation in removal efficiencies reported in the 
literature. These factors govern both reaction time and loading (Fernandez-
Fontaina et al. 2012), thus affecting biomass activity and concentration. 
Increasing SRT increases the diversity of the consortia of bacteria present in a 
treatment plant allowing the growth of the slower growing organisms that can 
only colonise the treatment plant at high sludge ages (Koh et al. 2009). 
Therefore, optimum conditions for bacterial activity may lead to increase 
biodegradation of micropollutants during treatment processes.   
The ASP can be applied in large and small volumes of wastewater. A 
disadvantage of the ASP is that the removal of pharmaceutical compounds 
varies between compounds, generating large quantities of solid sludge that 
requires additional treatment and cost for its disposal (Huber et al. 2014). 
 
2.7.2 Trickling filter 
Trickling filters (TF) are used to remove pollutants from wastewater as a part of 
an aerobic process, utilizing microorganisms attached to a medium. Wastewater 
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is generally spread over the media surface (rocks or plastic) using a rotating 
arm (Pearce and Edwards 2011). The removal efficiency of TF processes for 
micropollutants has been found to be less than 70% removal of 55 
pharmaceutical compounds studied. In comparison, the WWTP utilising 
activated sludge treatment gave a much higher removal efficiency of over 85% 
(Kasprzyk-Hordern et al. 2009b). Moreover, trickling filters, in comparison with 
other processes, are not the most efficient systems for the removal of 
pharmaceutical compounds (Bartelt-Hunt et al. 2009). 
 
2.7.3 Membrane bioreactors 
Membrane bioreactors (MBR) consist of a structure that integrates biological 
treatment with a membrane filtration system in a single procedure (Melin et al. 
2006). They were first reported in 1969 (Ng and Kim 2007). Membrane 
bioreactors can be operated at different SRTs (Verlicchi et al. 2010a), but the 
most important advantage of MBRs is that they can be operated at higher 
biomass concentrations; this results in smaller WWTP sizes and produces less 
sludge than the more conventional ASP. Several studies have examined the 
effectiveness of MBRs in the removal of pharmaceutical compounds (Clara et 
al. 2005b; Radjenovic et al. 2009; Kim et al. 2014). Kim et al. (2014) 
investigated the removal of 99 pharmaceutical compounds through a WWTP 
that employed an aerobic MBR; they found that the removal of compounds 
varied from 34–99%.  Although many studies (Verlicchi et al. 2010a; Radjenovic 
et al. 2009) have indicated that MBRs can remove several pharmaceutical 
compounds, no significant differences in the removal efficiency of certain 
 25 
 
compounds (e.g., ibuprofen, triclosan and caffeine) were found between the 
MBR and conventional ASP by Oppenheimer et al. (2007). Clara et al. (2005b) 
and Radjenovic et al. (2009) also compared the efﬂuent concentrations and 
removal rates for different pharmaceutical compounds in a conventional ASP 
and a MBR. Their results suggested that there were only slight differences, in 
favour of the MBR technology, in the removal efficiencies of pharmaceutical 
compounds. Moreover, for compounds that are persistent when treated with 
conventional ASP (such as carbamazepine), poor removal efficiencies were 
also found with MBR treatments (Clara et al. 2005b).  
As with ASP, the removal potential of MBRs also depends on factors such as 
the SRT. There are also some disadvantages of MBRs, which include higher 
capital costs, high costs of operation and maintenance, and high energy 
requirements of the air blowers and pumps (Clara et al. 2005b).  
 
2.7.4 Anaerobic processes 
Some pharmaceutical compounds can be removed from wastewater by their 
adsorption onto solids. Later, if the sludge is inadequately treated, the 
pharmaceutical compounds can enter the aquatic environment via the 
application of sludge to land for fertilization or through landfilling. Since 1999, 
sludge intended for land application in some countries has required advanced 
treatment through anaerobic digestion (Akunna and Bartie 2014). Anaerobic 
digestion processes are used to treat 75% of sludge that is generated in the UK, 
with the degree of treatment depending on the intended final use (Defra 2012).  
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Some studies have investigated the biodegradation efficiency of some 
pharmaceutical compounds under anaerobic processes (Carballa et al. 2007; 
Mussan et al. 2010). The reported biodegradation efficiency of pharmaceutical 
compounds has varied from no elimination to high elimination. For example, 
Carballa et al. (2007) observed significant elimination rates for some antibiotics 
and natural estrogens, while there was no elimination of carbamazepine. 
Mussan et al. (2010) investigated the fate of six pharmaceutical compounds 
(17α-ethynylestradiol, acetaminophen, acetylsalicylic acid, ibuprofen, metoprolol 
tartrate, and progesterone) during anaerobic digestion and only found a 
significant biodegradation potential for acetylsalicylic acid. The efficiency of 
anaerobic biodegradation is also affected by SRT (Lee et al. 2011). Anaerobic 
digestion uses less energy, and in fact produces energy in the form of methane 
generation. It is also a relatively easy process to operate, especially in hot 
climates. 
 
2.8 Factors effecting removal of pharmaceutical compounds in biological 
treatment systems 
The removal of organic compounds during biological treatments is influenced by 
many factors, such as the chemical and biological properties of the compound, 
wastewater characteristics, operational conditions, and the treatment 
technology used (Verlicchi et al. 2012a).  
2.8.1 Temperature 
Temperature conditions during biological wastewater treatment processes can 
significantly affect the microbial activity and growth (LaPara et al. 2000; Vieno et 
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al. 2005; Massmann et al. 2006). Akratos and Tsihrintzis (2007) found a positive 
linear correlation between temperature and the removal of COD, BOD5 and 
nutrients. In terms of pharmaceutical compounds, seasonal variations in the 
removal efficiency of some compounds in WWTPs were reported in Europe and 
North America, with lower removal efficiencies observed in winter at low 
temperatures (Heberer 2002; Kolpin et al. 2002; Metcalfe et al. 2003; Miao et al. 
2005). 
Castiglioni et al. (2006) reported that summer temperatures (average 18.6°C) 
had a strong positive effect on the removal efficiency of most compounds, 
compared to winter temperatures (average 9.7°C) (Table 2.7). 
 
Table 2.7: Average removal efficiencies of selected pharmaceutical compounds 
in winter and summer (Castiglioni et al. 2006). 
 
Compound Average removal efficiency (%) 
 
 Winter Summer 
Atenolol 10 55 
Bezafibrate 15 87 
Enalapril 18 100 
Furosemide 8 54 
Ibuprofen 38 93 
Ranitidine 39 84 
Sulfamethoxazole 17 71 
Amoxilline 75 100 
Ciprofloxacin 60 60 
Hydrochlorothiazide 30 30 
Ofloxacine 50 50 
Carbamazepine 0 0 
Clarithromycin 0 0 
Erythromycin 0 0 
Salbutamol 0 0 
 
These studies clearly demonstrate that higher temperatures improve the 
removal efficiencies of many compounds. However, little is known about the 
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fates of pharmaceutical compounds in tropical climates, where there are 
elevated temperatures year-round. Based on the reported effects of 
temperature on removal efficiencies of these compounds, it is expected that 
their removal efficiencies will also be relatively high in tropical temperatures. 
The concentrations of these compounds may, however, be higher in 
wastewaters in these countries due to higher water loss by evaporation. More 
information is therefore needed on the occurrence and fates of these 
compounds under tropical climatic conditions. 
2.8.2 Solids retention time 
Solids retention time (SRT) or sludge age is a parameter that is commonly 
optimised in the design of WWTPs, and indicates the mean residence time of 
microorganisms in the reactor. The SRT affects the performance of the 
treatment process, the aeration tank volume, the amount of sludge produced 
and the oxygen requirements (Jelić et al. 2012). Longer SRTs have been shown 
to influence and improve the elimination of pharmaceutical compounds during 
biological treatment (Falas et al. 2012; Koh et al. 2009).  
Clara et al. (2004) reported that longer SRTs (10 days) of ASP influenced the 
biodegradation efficiency of some pharmaceutical compounds, such as 
ibuprofen, bezafibrate, and oestrogens. A positive correlation was found 
between the removal rates of some compounds (ketoprofen and naproxen) and 
the SRT, up to 10 days, during an ASP treatment (Falas et al. 2012). By 
increasing the SRT in biological treatment processes, the slow growing 
microorganisms can grow and adapt to recalcitrant compounds, which lead to 
higher biodegradability efficiencies (Clara et al. 2004).  
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Diclofenac was significantly biodegraded when the SRT was at least 8 days 
(Kreuzinger et al. 2004). The removal efficiency of steroid oestrogens in a 
nitrifying/denitrifying AS WWTP, with phosphorus removal was > 90% (Koh et 
al. 2009). Gobel et al. (2007) found that long SRTs in MBRs increased the 
removal of some of antibiotics (roxithromycin and trimethoprim) from 39% and 
33% with a SRT of 16 days to 60% and 87% with a SRT of 60 days 
respectively. High removal efficiency (> 99%) was achieved for oestrogen in a 
MBR with a SRT of 60 days (Estrada-Arriaga & Mijaylova 2011).  
Overall, it is clear that the biodegradation of pharmaceutical compounds is 
better when longer SRTs are applied. However, many WWTPs are not 
designed with sufficiently long SRTs to achieve adequate removal rates 
(Nghiem et al. 2005). 
2.8.3 Hydraulic retention time  
Studies into the influence of HRT on the removal efficiencies of selected 
pharmaceutical compounds have reported varied results. Servos et al. (2005) 
found that an increase of the HRT improved the removal of oestrogen, whereas 
Weiss and Reemtsma (2008) indicated that the HRT does not affect oestrogen 
removal. Estrada-Arriaga et al. (2011) found that an increase in the HRT (to 12 
h) during MBR treatments enhanced the biodegradation of oestrogen (close to 
100%), as the microorganisms involved had time to adapt. In addition, a longer 
HRT (24 h) with SRT (10 d) significantly increased the removal efficiency of 
antibiotics (Kim et al. 2005). 
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2.9 Post-treatment  
2.9.1 Activated carbon  
Pharmaceutical compounds can be adsorbed by activated carbon (AC) in 
WWTPs. Several studies have analysed the effectiveness of powdered 
activated carbon (PAC) and granular activated carbon (GAC) (Gerrity et al. 
2011; Reungoat et al. 2012; Boehler et al. 2012; Serrano et al. 2011; Altmann et 
al. 2014). Generally, AC is found to have a great potential to remove organic 
micropollutants from wastewater. Snyder et al. (2007) studied the removal of 36 
organic compounds by AC, and found that over 90% of the compounds were 
removed. The removal efficiency of organic micropollutants by AC depends on 
the properties of the adsorption media and the characteristics of the compounds 
(Michael et al. 2013). According to Ternes et al. (2002) the elimination of 
selected pharmaceuticals (bezafibrate, clofibric acid, carbamazepine, and 
diclofenac) by AC during a drinking water treatment process was very effective, 
with the exception of clofibric acid.  
Generally, most studies have suggested that higher removal efficiencies (> 
90%) of micropollutants can be achieved with AC (Snyder et al. 2007; Adams et 
al. 2002 and Le-Minh et al. 2010); these including some pharmaceutical 
compounds that are not readily degraded by microorganisms (Altmann et al. 
2014). The advantages of AC include its simplicity of application and the 
possibility of the regeneration, or reuse, of exhausted GAC. However, its 
efficiency may be reduced by the presence of competing organic compounds in 
effluents (Altmann et al. 2014). This may, in turn, have a negative effect on the 
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microbial community (Callaway and Aschehoug 2000). It is also a relatively 
costly form of treatment (Crisafully et al. 2008). 
2.9.2 Advanced oxidation processes  
Advanced oxidation processes (AOPs) are a combination of processes that are 
mainly aimed at the formation of hydroxyl radicals (OH●) (Klavarioti et al. 2009). 
The OH-radicals can oxidize organic compounds including pharmaceutical 
compounds in wastewater. There have been several studies into the application 
of AOPs, such as ozone (O3), hydrogen peroxide (H2O2), titanium dioxide (TiO2) 
and ultraviolet (UV) techniques, for the treatment of water and wastewater 
(Ikehata et al. 2006; Giri et al. 2010; Hübner et al. 2013; Sui et al. 2014; 
Sundaram et al. 2014). Complete or partial degradation of pharmaceutical 
compounds in wastewater can be achieved using AOPs, through mineralisation 
to CO2 and H2O, or partial break down to other less harmful compounds. 
Normally, these technologies can be installed as a tertiary treatment after a 
biological (secondary) treatment in WWTPs. 
In laboratory experiments, Giri et al. (2010) examined the removal of 16 
pharmaceutical compounds in mixed solutions by seven AOPs (O3, UV, O3/UV, 
O3/TiO2, UV/TiO2, UV/H2O2, and O3/UV/TiO2). The ozone-based technique was 
powerful and removed about 90% of all the compounds, while the combination 
of O3/UV was the most appropriate technique for the simultaneous and effective 
removal of the selected compounds (Giri et al. 2010). A review of several 
studies that applied O3 to waters contaminated with pharmaceutical compounds 
indicated that although high degradation efficiency (measured by COD) is 
achievable, the degree of mineralisation was low and the ecotoxicity of the final 
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treated water persisted, or even increased (Homem and Santos 2011). Ikehata 
et al. (2006) also assessed the efficiency of AOPs in the removal of several 
pharmaceuticals from wastewater. They concluded that while some 
pharmaceuticals were efficiently removed by O3 (e.g., some antibiotics, 
carbamazepine, some NSAIDs, and oestrogen 17b-estradiol), other compounds 
had relatively low resistance (e.g., clofibric acid, diazepam, and ibuprofen), and 
N4-acetylsulfamethoxazole, a metabolite of sulfamethoxazole, was found to be 
more resistant to ozonation than the parent compound.  
The degradation of pharmaceutical compounds in wastewater that can be 
achieved with AOPs is dependent on factors such as the oxidant dose, 
concentration of pharmaceuticals, suspended solids, carbonate, bicarbonate 
and chlorine ions, pH, and temperature (Ikehata et al. 2006; Verlicchi et al. 
2010b; Homem and Santos 2011). Although, AOPs have the advantage of 
removing significant concentrations of micropollutants from wastewaters, the 
mineralisation of certain compounds is still only achieved at low rates, even for 
long treatment times. In addition, the oxidation process can lead to the 
increased toxicity of by-products that can also be more resistant than the parent 
compounds (Andreozzi et al. 1999; Dantas et al. 2008; Li et al. 2008). There are 
also high equipment and maintenance costs, as well as high energy 
requirements, for some of the AOPs, which constitute significant disadvantages 
to the treatment type (Homem and Santos 2011). 
 
 33 
 
2.10 Pharmaceuticals in drinking water 
After passing through WWTPs, the residues of pharmaceutical compounds 
enter receiving waters. Significant concentrations of these compounds in the 
receiving waters have been reported in several countries (Heberer 2002; Kolpin 
et al. 2002; Choi et al. 2008). There may have been instances in which 
pharmaceutical compounds have contaminated public drinking water through 
ineffectively treated wastewater being discharged into surface waters that 
eventually contribute to water supply sources (Benotti et al. 2008; Mompelat et 
al. 2009; Jelić et al. 2012a). In the summer of 2004, for example, newspapers in 
the UK reported that Prozac (fluoxetine) was detected in UK drinking water 
(BBC 2004). Thus, the efficient treatment of surface water before it is used for 
domestic water supply is also very important to avoid the presence of any 
pharmaceutical compounds in the drinking water. Table 2.8 shows the range of 
occurrences of selected pharmaceuticals that have been identified in drinking 
water (Jelic et al. 2012a).  
 
Table 2.8: Concentration ranges of selected pharmaceutical observed in 
 drinking water (Jelic et al. 2012a) 
 
Pharmaceutical 
compound 
Concentration range 
(ng/L) 
Atenolol  0.84–023 
Bezafiberate  1.90–027 
Cloﬁbric acid 5.30–270 
Gemﬁbrozil 0.80–070 
Diclofenac 1.00–035 
Ibuprofen 0.60–008 
Ketoprofen 3.00–008 
Acetaminophen          45.00–210 
Carbamazepine 9.00–258 
Phenazone        250.00–400 
Propyphenazone           80.00–240 
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Although, the observed concentrations of the compounds in drinking water 
(typically in the ng/L range) have not yet reached a serious or a health-
threatening level, it is prudent to reduce the levels of these compounds in 
surface water before any harm is experienced. 
 
2.11 Conclusions  
Although there are still many uncertainties about the consumption, occurrence 
and fate of pharmaceutical compounds emerging in HWW and MWWTPs, a 
number of conclusions can be drawn from the evidence discussed in this 
chapter: 
 Pharmaceutical compounds have been found in different surface waters 
all over the world, including rivers, lakes and oceans. Some compounds 
have then been found in drinking water supplies.  
 Hospitals can be significant point sources for some of the pharmaceutical 
compounds that are released into the water environment. 
 The contributions of hospitals to the concentrations of pharmaceutical 
compounds in municipal WWTPs vary from low (e.g., analgesics) to high 
(e.g., contrast media and antibiotics). 
 Conventional WWTPs can remove some pharmaceutical compounds, 
while other compounds are persistent and as a result are continuously 
discharged into surface waters. 
 The level of efficiency removal by biological treatments depends on the 
physico-chemical properties of the compounds, the type of wastewater 
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treatment technology, the HRT, the SRT and the climatic conditions (e.g. 
dilution, rainfall, temperature and level of sunlight). 
 Although, advanced treatment technologies can be efficient in the 
removal of most common pharmaceutical compounds, their capital and 
operational costs are often high. 
 Limited information exists on the occurrence and fate of micropollutants 
in tropical climatic conditions. 
 
In general, considerable uncertainties still remain about the fate of 
pharmaceutical compounds during common biological treatment processes 
under different operational conditions (mainly aerobic, anaerobic, SRT, HRT 
and temperature), which can affect the efficient removal of common 
pharmaceutical compounds. In order to develop new strategies to improve the 
treatment of these compounds, more detailed knowledge about the 
management and influencing factors are required under different conditions.  
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CHAPTER 3 
Materials, methods and analysis 
3.1 Selection of pharmaceutical compounds 
There are several thousand different licensed pharmaceutical products. The 
pharmaceutical compounds analysed in the present work were selected from 
eight different therapeutic classes, as follows: anti-inflammatories and 
analgesics, antibiotics, contrast media, β-blockers, anaesthetics, 
antidepressants, cytostatics and lipid regulators (Table 3.1). The compounds 
were selected from each therapeutic class based on the following criteria:  
 For each therapeutic class, the most commonly used pharmaceuticals 
were selected.  
 Potential presence of these compounds in wastewater as hospital drugs.  
 Potential effects on aquatic organisms.  
 Specific research interests (PILLS project 2012; Helwig et al. 2013) and 
previous measurement in wastewater and surface water (Yu et al. 2006; 
Lin et al. 2010).  
 The existence of analytical methods able to ensure a sensitive and 
reliable detection of the compounds during the different experiments. 
 
3.1.1 Analgesics and anti-inflammatories  
Paracetamol, naproxen and ibuprofen were selected as appropriate 
representative compounds of this therapeutic class. Painkillers in general are 
widely used and can be bought over the counter; paracetamol and ibuprofen 
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are some of the most commonly used with over 90 and 14 tonnes, respectively, 
dispensed annually in Scotland (Sniffer 2012). The contribution of hospitals to 
the overall load at wastewater treatment plants (WWTPs) may be relatively 
small (up to 30%), due to their general availability to the public (Helwig et al. 
2013). Ibuprofen and paracetamol have been detected at high concentrations in 
influents, effluents and receiving waters (Thomas et al. 2007; Wu et al. 2012). 
Analgesics, including naproxen and ibuprofen were found in two wild fish 
species downstream of a WWTP (Brozinski et al. 2012) and all three drugs 
(paracetamol, naproxen and ibuprofen) pose a potential eco-toxicological risk to 
organisms (PILLS project 2012; Verlicchi et al. 2012). Recently, the European 
Commission added a painkiller (diclofenac) to Directive 2013/39/EU of the 
European Parliament and of the Council, amending Directives 2000/60/EC and 
2008/105/EC as regards priority substances in the field of water policy, stating a 
limit to the annual average value for inland and other surface waters to be 0.1 
and 0.01 μg/L respectively (European Commission 2014). 
 
3.1.2 Antibiotics 
Five compounds, ciprofloxacin, clarithromycin, erythromycin, sulfamethoxazole 
and a metabolite of sulfamethoxazole, N-acetyl-sulfamethoxazole (NACS), were 
selected from the antibiotics therapeutic class (Table 3.1). Antibiotics are a 
diverse group of chemicals that can be divided into different subgroups such as 
β-lactams, quinolones, tetracyclines, macrolides and sulphonamides, among 
others (Kümmerer 2009). They are extensively used by humans for the 
prevention and treatment of diseases caused by microorganisms.  
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The contribution of hospitals to the load of antibiotics entering WWTPs vary 
from low concentrations to up to more than 100%. For example, hospital 
contributions in the UK have been reported to be about 75% for ciprofloxacin 
and 36% for clarithromycin; in Luxembourg they were 155% for ciprofloxacin, 
53% for sulfamethoxazole and 64% for erythromycin and in Denmark they were 
59% for clarithromycin and 82% for erythromycin (Helwig et al. 2013). 
Ciprofloxacin, in particular, is used in European hospitals and is not efficiently 
removed by WWTPs (Thomas et al. 2007). 
Antibiotics have adverse effects on aquatic organisms. Their occurrence in 
wastewaters is correlated to bacterial resistance and a reduction in microbial 
activity (Niu et al. 2013; Herzog et al. 2013). In addition to bacteria, algae can 
be highly sensitive to different antibiotics (Isidori et al. 2005; Van der Grinten et 
al. 2010). The genotoxicity of some antibiotic compounds such as ofloxacin and 
sulfamethoxazole has been demonstrated (Isidori et al. 2005). Ciprofloxacin has 
also been reported to damage the DNA of bacteria in hospital wastewater 
(Hartmann et al. 1999).  
The metabolite of sulfamethoxazole, NACS, was selected for this study 
because high doses of sulfamethoxazole are excreted by humans in the form of 
NACS (Gobel et al. 2005) and it can be converted back to the parent compound 
during wastewater treatment processes.  
 
3.1.3 Contrast media 
Contrast media are mainly dispensed during radiology applications at hospitals. 
They are excreted by patients (up to 100%) and are highly persistent during 
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wastewater treatment (Weissbrodt et al. 2009). The contributions of hospitals to 
iopamidol loads to WWTPs have been measured at 100% in the UK (Helwig et 
al. 2013). Therefore, two compounds (diatrizoate and iopamidol) were selected 
for this work (Table 3.1). 
 
3.1.4 β-blockers 
β-blockers, such as atenolol, are used for the treatment of high blood pressure 
and are prescribed during recovery from heart attacks. Around 90% of ingested 
atenolol is excreted by patients in the form of the active parent compound 
(Sniffe 2013). Although this compound is not a typical hospital drug, it has been 
detected in wastewaters, surface waters and ground waters, indicating that it is 
not sufficiently removed by WWTPs (Dordio et al. 2009). For example, the 
concentrations of atenolol in effluents from selected hospitals were measured at 
up to 3.4 µg/L (Gomez et al. 2006). An eco-toxicological study showed that 
most of the β-blockers tested had a specific toxic effect towards green algae 
(Maurer et al. 2007). Atenolol was therefore selected as suitable for this study. 
 
3.1.5 Anaesthetics  
Lidocaine was selected for measurement in this study (Table 3.1) because it is 
widely used as a local anaesthetic. Lidocaine has been detected in 
wastewaters, surface waters and ground waters (Rúa-Gómez et al. 2012). The 
contribution of hospitals to the lidocaine loads entering WWTPs have been 
analysed and were found to be 81% and 61% in the UK and Luxembourg, 
respectively (Helwig et al. 2013). 
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3.1.6 Antidepressants 
Carbamazepine is used alone or in combination with other medications to treat 
mental illnesses, depression, post-traumatic stress disorder, drug and alcohol 
withdrawal, restless leg syndrome, diabetes insipidus, certain pain syndromes, 
and a disease in children called chorea (Mohapatra et al. 2013). 
Carbamazepine is not generally administered in hospitals, but it is the most 
frequently detected pharmaceutical residue in water bodies (Thomas & 
Langford 2007; Zhang et al. 2008). It has also been reported to be ubiquitous in 
Welsh rivers (Kasprzyk-Hordern et al. 2008 a, b). Therefore, carbamazepine is 
included for further study.  
 
3.1.7 Cytostatics  
Cytostatics are anti-cancer drugs that may have carcinogenic, mutagenic, 
teratogenic and fetotoxic effects (Kümmerer et al. 1997). Cytostatics have 
frequently been detected in water bodies, indicating that they are only partially 
removed by conventional wastewater treatment plants (Zhang et al. 2013). In 
the UK, the contribution of hospitals to the load of ifosfamide to WWTPs was 
found to be up to 100% (Helwig et al. 2013). Therefore, cyclophosphamide and 
ifosfamide were selected for study.  
 
3.1.8 Lipid regulators 
Bezafibrate is a fibrate drug that is currently used extensively as a lipid 
regulating agent and has been detected in a variety of different aquatic systems 
(Yuan et al. 2012). The bioaccumulation and biomagnification of bezafibrate 
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could potentially be very harmful to organisms in the aquatic environment, 
because of a possible mixture of toxicity, synergistic and additive effects (Li et 
al. 2014). Isidori et al. (2007) studied the general toxicity and genotoxicity of 
fibrates and their photoproducts on organisms (bacteria, rotifers and 
crustaceans) and found that acute toxicity occurred at concentrations in the 
order of dozens of mg/L for all the trophic levels tested. However, chronic 
exposure to these compounds caused an inhibition of population growth in 
rotifers and crustaceans. Therefore, bezafibrate was selected as suitable for the 
purposes of this study.  
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Table 3.1: Pharmaceutical compounds selected for monitoring. 
Pharmaceutical 
class 
Compound PNECa 
(μg/L) 
Brief reasons 
Analgesics and 
anti-
inflammatories 
Paracetamol  1  Found in surface water 
 Bought over the counter 
 Relatively low PNEC 
Naproxen 2.62 
Ibuprofen  1.65 
Antidepressant Carbamazepine    13.8  Found in surface water 
 Persistent in WWTPs  
Lipid Regulators  Bezafibrate         5.3  Chronic exposure inhibits 
growth of some organisms 
 Relatively low PNEC 
Anaesthetics  Lidocaine 82    High hospital contribution 
 
Antibiotics  Ciprofloxacin 938  High hospital contribution 
 High effects on aquatic life 
 Low PNEC except 
ciprofloxacin 
 
Clarithromycin 0.07 
Erythromycin 0.02 
Sulfamethoxazol
e 
  0.027 
Metabolite of 
sulfa- 
Methoxazol 
NASCS    n/a 
Contrast media  Diatrizoate   11000 
 
 Up to 100% excretion  
 Hospital specific 
substances 
 Persistent in wastewater 
treatment 
Iopamidol 380000 
Cytostatics Cyclophosphami
de 
11  Persistent in WWTPs 
 High hospital contribution 
Ifosfamide 11 
β-blockers Atenolol 30  Up to 90% excretion 
 Found in surface water 
 Persistent in WWTPs 
a Predicted No Effect Concentrations (PNEC) from (Verlicchi et al. 2012a) except for 
the contrast media, for which the PNEC are from (PILLS project 2012, cited form 
http://www.wikipharma.org/api_data.asp) 
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3.2 Selection locations of wastewater treatment plants  
In this research, the fate of pharmaceutical compounds during wastewater 
treatment is studied in four WWTPs in the UK (Tayside and Fife, Scotland) and 
two in Saudi Arabia (Riyadh). The choices of these locations were based on 
different factors, which were as follows: 
1. Different management practices at the point source (hospital): while 
most hospital wastewater (HWWs) are directly released into urban 
sewerage networks in the UK for co-treatment with municipal wastewater 
(MWW), HWWs are often pre-treated (on-site treatment) in Saudi Arabia 
(more details about HWW management are provided in Chapter 4). 
2. Different treatment processes: the WWTPs selected represent cross-
sections of common types of water treatments in the UK and Saudi 
Arabia, including activated sludge process (ASP), trickling filter (TF) and 
tertiary treatment.    
3. Different climatic conditions. These can affect key factors in the 
operational processes, such as the ambient temperature and dilution by 
from rainwater. The annual average temperatures in the UK are 7–11°C 
(BBC 2014), while in Saudi Arabia; the average temperature exceeds 
26-28°C (Qadir et al. 2010; Almazroui et al. 2014). Saudi Arabia is an 
arid region with limited water resources, in contrast to the UK, which has 
high rainfall. Different climatic conditions (e.g. dilution, rainfall, 
temperature and levels of sunlight) will have different effects on the 
biodegradation kinetics during biological treatment, by affecting the 
microbial activity (Cruikshank & Gilles 2007; Pauwels and Verstraete 
2006; Verlicchi et al. 2012a; Kasprzyk-Hordern et al. 2009b). Therefore, 
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Saudi Arabia (which has a tropical climate) and UK (which has a 
temperate climate) were selected for this work as they experience 
different and contrasting environmental conditions.  
 
3.2.1 United Kingdom 
The four municipal wastewater treatment plants (MWWTPs) chosen in the UK 
(Hatton, Cupar, Guardbridge and Letham) (Figure 3.1) were selected because 
they encompass a range of service areas (from a large city to a small village) 
and also use different types of treatment and have different operational 
characteristics (Table 3.2) that may likely affect the fate of the chosen pollutants 
in the plants. 
 
 
Fig. 3.1: The locations of WWTPs in Scotland, UK (1 Hatton, 2 Guardbridge, 
3 Cupar and 4 Letham). 
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Table 3.2: Characteristics of selected MWWTPs in Scotland, UK 
 
Parameters Hatton Cupar Guardbridge Letham 
 
Process technology Activated 
sludge 
Activated 
sludge 
Activated 
sludge 
Trickling 
filter 
Biological process Non 
nitrifying 
Nitrifying Nitrifying Nitrifying 
PE 237,000 16,000 6,000 300 
HRT(hours) 4 16 17 n/a 
SRT (day) n/a 9 11 n/a 
Ambient Temp (°C) 8±2 8±2 8±2 8±2 
 PE = Population equivalent; HRT = Hydraulic Retention Time; SRT = Solid 
Retention Time; n/a = not available 
 
 
Hatton MWWTP serves a major city (Dundee) and a large town (Arbroath) and 
processes the wastewater of around 237,000 people. It receives wastewater 
from multiple different sources (e.g. households, hospitals, shops, industries, 
veterinary clinics, runoff etc.). According to an email received from Gillian 
Marnie of NHS Tayside, there are many hospitals in Dundee, including 
Ninewells Hospital (a major NHS and medical school hospital), King Cross 
Hospital, Royal Victoria Hospital and BMI Fernbrae Hospital (Table 3.3). 
Ninewells Hospital is one of the largest teaching hospitals in the UK, with 15 
operating theatres, 40 wards, and 5000 employees. The hospital contains about 
849 beds and has a full range of healthcare specialties (Healthcare 
Improvement Scotland 2015). It receives patients from the city of Dundee and 
the surrounding region. The contribution of these hospitals, like others, to the 
loads of pharmaceutical compounds at WWTPs may vary based on different 
administration routes, excretion and the frequency of use of compounds 
(Helwig et al. 2013). The wastewaters from the hospitals that are directly 
connected to the Hatton plant are co-treated with the MWW.  
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The Hatton MWWTP employs primary (gravitational settlement) and secondary 
treatment (aerated sludge) with no nitrification process and secondary clarifier. 
The treated effluent is discharged into the River Tay. The Hatton plant also 
treats solid sewage through anaerobic processes.  
 
The Cupar MWWTP is located in Cupar, a town in Fife, and serves a population 
of around 16000 people. The MWWTP receives raw wastewater from 
households, shops, two hospitals and veterinary clinics. According to an email 
received from Norma Aitken of NHS Fife, the hospitals are Adamson and 
Stratheden, with 186 beds in total (Table 3.3). Both hospitals are community 
hospitals serving Cupar and surrounding areas. Healthcare services include 
various specialist units (e.g. physiotherapy, occupational therapy, podiatry, 
dietetics and speech and language therapy). The Cupar MWWTP employs 
solids screening, biological treatment with a long aeration time that promotes 
nitrification, and a secondary clarifier. The final treated effluent is discharged 
into the River Eden.  
 
Guardbridge MWWTP is located on the River Eden, near the coast, and serves 
about 6,000 people. Most of the raw wastewater comes from households and 
shops but hospital wastewater is not included. Treatment at the plant consists 
of grit removal, biological treatment with a long aeration time that promotes 
nitrification and a secondary clarifier. The final treated effluent is discharged 
into the River Eden. 
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Letham MWWTP serves a small village with a population of less than 300 
people. Most of the raw wastewater is generated from households and there is 
no hospital in the area. The MWWTP employs the following components: solids 
screening, primary settlement, secondary treatment (trickling filter) and a 
secondary clarifier. The Letham effluent is discharged into a small lake.  
 
Table 3.3: Hospitals covered by each plant 
 
Plant 
 
Hospital Bed Average 
Inpatient 
per year 
Average 
consumption 
water per year 
Hatton 
 
 
 
 
Ninewells  849 64164 435232 m3 
Royal Victoria 72 1244 2261 m3 
Kingsway Care  59 153 4882 m3 
Carseview 
Centre 
52 606 7266 m3 
Fernbrae  15    n/a          n/a 
Bluebell 
Intermediate 
care  
23 
 
 
261 n/a 
 
Cupar 
 
Adamson 
 
18 
 
179 
 
1300 m3 
Stratheden 168 518      9075 m3 
 
Guardbridge 
 
No hospitals 
 
- 
 
- 
 
- 
 
Letham 
 
No hospitals 
 
- 
 
- 
 
- 
 
 
3.2.2 Saudi Arabia  
The monitoring of wastewater treatment in Saudi Arabia in this study is 
comprised of two hospital wastewater treatment plants (HWWTPs) in Riyadh, 
the capital city. HWWTPs are located in the west and south of the city (Figure 
3.2). The choice of these locations was based on the following factors;  i) they 
have onsite treatment ii) they provide a whole range of medical services (e.g. 
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internal medicine, maternity, radiology, cardiology, surgery, kidney disease, 
dermatology, urology, orthopaedic, paediatric, obstetrics and gynaecology, 
dentistry, pharmacy and medical laboratory services, among others). The 
HWWTPs at both hospitals employ ASPs. There are no other HWWPs in 
Riyadh (or perhaps the entire country) that employ alternative treatment 
processes.  Due to limited access to data, some of the information on 
operational processes was not available (e.g. hydraulic retention time and 
solids retention time, among other operational parameters that are commonly 
measured). The first of the HWWTPs is located in Salman Hospital, while the 
second one is in Iman Hospital (Figure 3.2). Both HWWTPs are operated by the 
respective hospital authorities under the direct control of the Saudi Arabian 
Ministry of Water and Electricity. 
 
Hospital Drugs monitoring: Communication with the pharmacology department 
(for both Saudi Arabian hospitals) indicated that ibuprofen, naproxen, 
diatrizoate, iopamidol and fosfamide are not commonly prescribed within either 
hospital. Therefore, these compounds were not analysed in the influent and 
effluent samples from these hospitals. In contrast, erythromycin (an antibiotic) 
was confirmed as being commonly used within the hospitals, so it was selected 
for analysis.  
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Fig.3.2: The location of on-site HWWTPs selected in Riyadh city, Saudi Arabia. 
SH: Salman Hospital; IH: Iman Hospital; RCWWTP: Riyadh central wastewater 
treatment plant (Google Map 2014). 
 
 
Salman hospital wastewater treatment plant (SHWWTP): Salman Hospital is an 
important general hospital that employs 3000 people and has 300 beds. At the 
time of writing, it is being extended to a capacity of 450 beds. Salman hospital 
covers patients from the west and north of Riyadh and offers a large range of 
general medical services. In 2013, 8523 inpatients left the hospital. About 
328,050 m3 of water was used in 2013, equivalent to about 896 m3/day. 
The SHWWTP receives wastewater from all of the hospital’s departments and 
systems, including outpatients and inpatients, medical units, restaurants, 
laundry and the air conditioning systems. The treatment processes the 
SHWWTP employs consist of screening, aeration tanks (secondary treatment), 
a secondary clarifier and sand filtration, followed by a chlorination process 
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(Figure 3.3). The final treated effluent is discharged to the sewerage system 
that leads to the Riyadh central WWTP. 
Imam hospital wastewater treatment plant (IHWWTP): Iman hospital employs 
2042 people and contains 215 beds. It also offers a wide range of general 
medical services, as described above, apart from a kidney disease unit. In 
2013, the total water consumption of the hospital was 220,100–230,100 m3, 
across all hospital departments, including general services (i.e. restaurants, 
laundry and air conditioning systems). The IHWWTP processes are made up of 
screening, primary settlement, aeration tanks, a secondary clarifier, sand 
filtration and chlorination (Figure 3.3). The final treated effluent is also 
discharged to the sewerage system for further treatment at the Riyadh central 
WWTP. 
 
 
 
 
Fig. 3.3: Schematic of the treatment processes employed in Riyadh, (a) 
Salman Hospital and (b) Iman Hospital wastewater treatment plants (X = 
sampling point). 
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3.3 Sample collection 
 
The removal of pharmaceutical compounds from WWTPs occurs either by 
biodegradation and/or adsorption onto sludge. Most of the removal of 
pharmaceutical compounds occurs as a result of degradation (Ternes et al. 
2004; Radjenović et al. 2009). Removal by adsorption onto sludge is generally 
quite low (<20%) except for some antibiotics (Verlicchi et al. 2012a,b). In 
addition, pharmaceutical compounds have little tendency to adsorb onto sludge 
at neutral pH (Uraes and Kikuta 2005). Therefore, although a bigger picture 
would be gained by analysing the sludge and liquid samples of each WWTP, 
only aqueous samples were collected and analysed in this research due to 
financial limitations. 
 
3.3.1 United Kingdom 
Samples were collected from two points (before and after secondary treatment) 
as marked by (X) in Figure 3.4. Sampling was carried out in winter (3 October–
9 November 2012) and also in summer (3–28 June 2013). A minimum of two 
samples were taken weekly for four weeks in winter (with an average air 
temperature of 6.5°C) and also for four weeks in summer (with an average air 
temperature of 13.2°C) from each site over a 5 hour period (09.00 h–14:00 h). 
All the samples were collected in 500 mL sterile plastic bottles (UK Water, UK) 
and immediately transferred to the laboratory for the analysis of conventional 
parameters. 150 ml of each sample was frozen at –20oC for the analysis of the 
pharmaceutical compounds. Therefore, across all time points 1200 mL of 
sample was obtained from each sampling point at each site (for example, a 
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total of 600 mL influent collected from Cupar plant in winter was mixed with the 
corresponding 600 mL collected in summer time) for every plant. Due to the 
expense of analysing pharmaceutical compounds, the winter and summer 
samples taken at each sampling point were mixed together to obtain average 
values over both seasons. 
 
 
Fig. 3.4: Schematic of the treatment processes employed in UK, (a) activated 
sludge and (b) trickling filter (X = sampling point). 
 
 
3.3.2 Saudi Arabia 
Samples were collected from two points, before the secondary treatment and 
after the tertiary treatment process as marked by (X) in Figure 3.3. Sampling 
was carried out twice weekly for four weeks in April 2014. Samples were 
collected in the middle of the day (11:00-14:00) when the air temperature was 
at its highest (30-35 °C). This is in anticipation that the temperature of the 
surface water would have been warmest at this time of day. The samples were 
collected in 1 L sterile plastic bottles (Saudi Water, Saudi Arabia) and 
transferred in a cool box to the laboratory at the School of Science, King Saud 
University (KSU) for the analysis of conventional parameters. 400 ml of each 
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sample were frozen at –20oC for the analysis of the pharmaceutical 
compounds.   
All the samples collected from each respective sampling point were mixed 
together and three aliquots of 1000 mL were taken for analysis of the 
pharmaceutical compounds.  
 
3.3.3 A note on sampling  
Excreted drug residues in sewers can be subject to high short-term fluctuations, 
due to toilet flushes and diurnal variations (Ort et al. 2010). The influence of the 
sampling methodology on data accuracy depends on the number of pollutant 
peaks and the sampling frequency; sampling intervals of five minutes or shorter 
may be required to properly account for temporal variations in the 
pharmaceutical compounds present in influents and to ensure that no toilet 
flushes are missing (Ort et al. 2010). In addition, Gardener et al. (2013) 
indicated that, a minimum of two samples are necessary from each site over a 
12-hour period in order to assess within-day variability. However, in this study, 
these potential short term variations in pharmaceutical compound loading were 
not put into account due to restrictions with regard to time and the availability of 
sampling facilities. Furthermore, mixing of the samples as explained in sections 
3.3.1 and 3.3.2 was carried out in an attempt to cost effectively reduce the 
effects of the fluctuations.  Therefore, collected sampling uncertainty may add 
some variation to the concentrations of pharmaceuticals in samples.  
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3.4 Analysis of conventional parameters 
The chemical oxygen demand (COD), total organic carbon (TOC), nitrate (NO3) 
and ammonium (NH4) were analysed according to the manufacturer’s 
instructions for the Spectrophotometer, model DR 5000 (Hach Lange, 
Germany). Biochemical oxygen demand (BOD5) was analysed according to the 
Standard Methods for the Examination of Water and Wastewater (APHA, 
1998).  
 
3.5 Analysis of pharmaceutical compounds 
The pharmaceutical compounds were analysed as described by Helwig et al. 
(2013) and illustrated in Figure 3.5. This method was developed by the School 
of Engineering and Built Environment, Glasgow Caledonian University (GCU) 
and was chosen to ensure the detection of the compounds of interest. 
 
3.5.1 Sample preparation 
In the UK, the samples were prepared for LC-MS/MS analysis by filtration, 
extraction, elution and drying down. The wastewater samples (1000 mL) were 
filtered through 100 µm, 1.6 µm and 0.7 µm glass microfiber filters (Whatman, 
UK) and then a 0.45 µm cellulose nitrate membrane sterile filter (Whatman, 
UK), to remove any suspended particulate matter. Each filtered sample was 
adjusted to pH 2.0 (± 0.1) through the addition of 0.5 M hydrochloric acid. Solid 
phase extraction (SPE) cartridges, Strata-X, 1 g/20 mL, 33 polymeric reserved 
phase (Phenomenex, UK) were pre-conditioned with methanol (2 mL) and 
distilled water (2 mL). Then, the samples were loaded at a flow rate of 10 
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mL/min, using an SPE vacuum manifold with 12 holes (Macherey-Nagel, 
Germany). The cartridges were dried under vacuum and washed 3 × 2 mL with 
water, before being eluted with 4 × 2 mL CH3CN/MeOH containing 0.1% formic 
acid. The samples were then dried down under nitrogen. The dried-down 
samples were re-constituted in CH3CN/H2O (30/70). The samples were then 
diluted further (1:8) by removing 100 ul aliquot and adding 700 ul CH3CN/H2O. 
Deuterated internal standards were added to afford a concentration of 5 ug/L 
prior to liquid chromatography/tandem mass spectrometry analysis. 
 
Triplicate samples (1000 mL) from the HWWTPs in Saudi Arabia were partially 
processed (filtration and extraction) at the School of Science, King Saud 
University (KSU). The same processes and materials (filters and cartridges) as 
those described above were applied, with one difference: the samples were 
loaded at a flow rate of 10 mL/min using an SPE vacuum manifold with 24 
(instead of 12) holes (Waters USA). At this point, the cartridges were dried 
under vacuum for a few minutes and then frozen at −20°C. Then, all the 
cartridges were transported back to the UK (Abertay University) in a cool box 
(journey duration about 9.5 hours). All of the remaining steps (elution, drying 
down, reconstitution and the incorporation of standards) were carried out as 
above. 
 
3.5.2 HPLC-MS analysis  
The extracts for all samples were analysed at Glasgow Caledonian University. 
Two different types of equipment were used. The UK samples were analysed 
by LC-MS/MS in 2013. The equipment used for this analysis became faulty and 
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therefore the Saudi Arabian samples were analysed in 2014 using new 
equipment, as described below: 
 
 UK samples 
Chromatographic separation of the analytes was performed by LC-MS/MS 
(Agilent 1100 series LC system, autosampler) using an Atlantis dC18 3 μm, 2.1 
× 150 mm column (Waters, UK). A binary gradient with a flow rate of 0.2 
mL/min was used; the mobile phase A used was acetonitrile and the mobile 
phase B was ammonium formate (10mM)/formaic acid/water, adjusted to pH 
3.5. The gradient was run from 1% to 99% organic over 45 mins. The column 
oven was maintained at 30 ± 2°C. The sample injection volume was 10 µL and 
the auto-sampler was operated at room temperature. The detector was an 
Esquire 3000 plus Ion Trap mass spectrometer (Bruker Daltonics UK).  
 
 Saudi Arabia samples 
Chromatographic separation of analytes was also performed by LC-MS/MS 
(Thermo Scientific Q Exactive Quadrupole-Orbitrap Mass Spectrometer) using 
an Xselect HSS T3. 2.1 × 150 mm column (Waters, UK). The same flow rate, 
mobile phases, and gradient were used, but this was carried out over 33 mins 
(instead of 45 mins).  
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Fig.3.5: Schematic of the analytical methods performed to determine the 
concentrations of pharmaceutical compounds in the WWTP samples. 
 
 
 
3.6 Biodegradation experiments 
Short-term batch biodegradability tests were conducted for selected target 
pharmaceutical compounds in order to evaluate their individual fate under 
biological aerobic and anaerobic conditions. These biological conditions occur 
in wastewater treatment systems, the wastewater transport in sewers, storage 
and in the key treatment units of the wastewater treatment plants selected for 
this study (as indicated in sections 3.2.1 and 3.2.2). The concentrations of 
pharmaceutical compounds in wastewater are normally between µg/L and ng/L.  
In order to check the representativeness of studies at concentrations that are 
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more readily tested and analysed, a markedly higher concentration of 1 mg/L 
was used for pollutants in experiments. 
 
3.6.1 Chemical compounds 
The pharmaceutical compounds were obtained from Sigma-Aldrich (Sigma-
Aldrich®, UK): paracetamol (CAS-Number 103-90-2), ibuprofen (CAS-N. 15687-
27-1), naproxen (CAS-N. 22204-4-531) and sulfamethoxazole (CAS-N. 723-46-
6). Due to the pharmaceutical compounds have sparing solubility in water, 
methanol was used to dissolve each of the compounds and a stock solution 
was prepared that contained all of the pharmaceutical compounds.  
 
3.6.2 Synthetic wastewater  
Synthetic wastewater was used for the biodegradation experiments (Table 3.4). 
The composition of the synthetic wastewater used in this study is based on a 
synthetic feed with characteristics from Shanmugam and Akunna (2008), with 
minor modifications.   
 
3.6.3 Seed biomass   
For the aerobic biodegradability experiment, seed biomass was collected from 
the secondary effluent of the Guardbridge MWWTP (an activated sludge 
process plant) in 500 mL sterile plastic bottles (UK Water, UK) and transported 
directly to the laboratory. The seed effluent was stored at 4°C for less than 24 
hours before being used. The seed effluent was collected from the Guardbridge 
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MWWTP because the plant applies ASP that has a longer SRT and HRT (Table 
3.2).  
For the anaerobic biodegradability experiment, because Hatton MWWTP is the 
only plant that also has an anaerobic sludge digestion process for sludge 
treatment, anaerobically digested sludge seed (1000 mL) was collected from 
there and transported to the laboratory, where it was stored at 37°C. The 
characteristics of the sludge at the time of inoculation in the experiments were: 
pH = 7.70, total solids (TS) = 25.21 g/L, volatile solids (VS) = 14.29 g/L and 
volatile fatty acids (VFA) = 259 mg/L.  
 
Table 3.4: Composition of synthetic wastewater. 
Name 
 
Compound Concentration 
mg/L 
Ammonium Bicarbonate NH4HCO3 200 
Potassium Phosphate KH2PO4   80 
Glucose C6H12O6   10 
Magnesium Sulphate MgSO4     1 
Iron FeCl3               1 
Calcium chloride CaCl2     1 
Potassium chloride KCL     1 
Cobalt chloride CoCL2        0.2 
Nickel chloride NiCL2        0.2 
BOD5 
TS 
 11-15 
190-220 
 
 
3.6.4 Aerobic biodegradability batch tests 
Two aerobic batch tests were conducted in 275 mL bottles. Each bottle 
contained synthetic wastewater (10 mL), seed effluent (10 mL) and the drug 
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stock solution (1 mg/L), and was made up to 275 mL using fully aerated dilution 
water. The bottles were kept in an incubator at 20 ± 1°C. Samples (200 mL) 
were taken at different retention times in order to detect the concentration of the 
selected pharmaceutical compounds remaining. The aerobic batch tests were 
performed at 20±1oC in this study, which is conventional standard temperature 
usually used in wastewater organic aerobic biodegradability tests (Dytczak et al. 
2006; Myers & Wilde 2003; SWITCH 2008).  
 
3.6.5 Anaerobic biodegradability batch tests  
Duplicate batches and blank cultures were prepared for pharmaceutical 
compounds using different retention periods. Sludge (1000 mL) from the Hatton 
anaerobic sludge process was added to 2000 mL of synthetic wastewater and 
the final mixture volume was made up to 3500 mL with distilled water. The 
pharmaceutical compound stock solution (1 mL/L) was added into the mixture 
after a blank sample was taken. Then, 200 mL samples were withdrawn and put 
into 500 mL bottles. These bottles were purged with nitrogen gas for 2 minutes 
(in order to displace the oxygen), then each was sealed with a rubber septum 
and an aluminium cap. The cultures were then incubated at 37°C (commonly 
used optimum mesophilic temperature for anaerobic wastewater treatment 
processes (Musson et al. 2010; Carballa et al. 2007; Angelidaki & Sanders 
2004). Each bottle was manually shaken a few times every 24 hours. Samples 
(200 mL) were taken to determine the pH and the concentration of the 
pharmaceutical compounds.  
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3.6.6 Sample analysis  
The fates of the pharmaceutical compounds in the batches were analysed using 
the same method that was employed to monitor the compounds in the UK 
MWWTPs, as reported above (section 3.5.1 and 3.5.2) and is illustrated in 
Figure 3.6. 
 
Fig. 3.6: The analytical method applied to determine the biodegradation of 
selected pharmaceuticals in batch experiments. 
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CHAPTER 4 
Hospital Wastewater Management in the UK and Saudi Arabia  
4.1 Introduction:  
Wastewater treatment plants, especially those receiving hospital wastewater, 
are important point sources of entry of pharmaceuticals compounds into the 
aquatic environment. In many countries, HWW is connected with urban sewage 
and co-treated in MWWTP. However, in some countries on-site hospital 
wastewater can receive pre-treatment and legislation in the field of water, 
wastewater and the environment may be different from country to country.  
Until recently, little has been reported on the performance of different 
wastewater treatment processes, in various parts of the world, in the removal of 
pharmaceutical compounds. In order to contribute to the limited data on the 
subject, two different locations (UK and Saudi Arabia) have been selected as 
part of this study to assess the performance of current management and 
treatment practices on the treatment of selected pharmaceutical compounds 
often found in some municipal and hospital wastewaters. This section reviews 
current common management and treatment strategies of hospital wastewater 
including the collection, treatment and disposal. 
 
4.2 Current hospitals wastewater management in the UK 
Several thousand pharmaceutical compounds are used for a range of purposes 
worldwide. In the UK, there are about 3000 active substances that are licensed 
for use (Barcelo 2005). In hospitals, a wider variety of chemicals, in addition to 
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pharmaceuticals are used for medical purposes. These compounds are used in 
very large volumes and their consumption is rising year by year (Chapter 2). 
Pharmaceutical compounds in receiving waters have been linked to the 
disruption of the sexual activities of fish in UK waters (Van Aerle et al. 2001; 
Cheshenko et al. 2008). Effective and comprehensive hospital wastewater 
management is thus important in reducing environmental risks related to 
pharmaceutical compounds.  
To control the release of these compounds in the environment in the UK, Water 
UK recently issued National Guidance for Health Care Wastewater Discharges 
(NGHCAD) (Water UK 2011).  This guidance clarifies requirements for 
preventing environmental harm from hazardous pollutants.  
 
4.2.1 Hospital wastewater collection  
In the UK, most hospital sewers are directly connected to the urban sewer and 
both hospital and municipal wastewater are co-treated in municipal wastewater 
treatment plants (MWWTPs). Sewer networks cover about 96% of the UK 
population, and the remaining 4% represents small communities and individual 
properties in rural areas not covered by sewer networks (Defra 2012). There is 
more than 624,200 km of sewer networks in the UK that collect wastewater 
from homes, industries, rainwater run-off from roads and from other sources, 
including healthcare services. There are three main methods of wastewater 
collection in the UK (Defra 2012): 
 Surface-water drainage (rainwater run-off from roads and urban areas are 
collected and discharged into local receiving water). 
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 Combined sewerage (rainwater run-off is collected with wastewater from 
domestic, industrial, commercial and other premises, including hospital 
wastewater). 
 Foul drainage (wastewater only).   
Both surface water and foul drainage may eventually connect to combined 
sewerage. The combined sewerage system is not uncommon in the UK as well 
as other countries in Europe (Defra 2012). 
According to the NGHCWD guidelines, there are three categories that 
healthcare products will be classified into with regards to discharge into the UK 
sewerage system:  
 Discharge into the sewer is prohibited (e.g. excess liquid anesthetics in 
syringes, pharmaceuticals classified as cytotoxic/cytostatic and radioactive 
materials are not allowed to be discharged to sewers) and should be 
appropriately disposed. 
 Approval is required before discharge to sewer (e.g. preservatives, fixatives 
and test pharmaceutical products or substances used in their 
manufacturing); in this case, the hazardous properties of the product 
ingredients are not fully known. Therefore, hospitals should ask the local 
sewerage operator for decisions regarding discharges. 
 No prohibition on discharge to sewer (e.g. small quantities of reagents, non-
pharmaceutically active products and domestic services). 
In addition, NGHCWD further stipulates a strong recommendation for hospitals 
to prepare emergency plans for any spillage status, loss of water supply and 
drainage plans for any materials that are prohibited. 
 65 
 
4.2.2 Hospital wastewater treatment  
There are about 9000 WWTPs in the UK, involving some or all of the following 
four main stages (Defra 2012): 
 Preliminary treatment 
 Primary treatment 
 Secondary treatment (biological treatment) 
 Tertiary treatment: using advance treatment processes to reduce 
different pollutants. 
In order to determine the required stages for any WWTP, the population 
equivalent (PE) and type of receiving water are the most important factors to 
consider according to the European Commission Urban Wastewater Treatment 
Directive (EC-UWWTD) as shown in Table 4.1 (EUWWTD 2006). As reported 
above, hospital wastewater is normally discharged into the public sewer system 
and both hospital and municipal wastewater are co-treated in MWWTPs 
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Table 4.1: Treatment stages for WWTPs in the UK (EUWWTD 2006) 
Population 
Equivalent 
By end   
of 
Receiving  
water 
Specified 
Treatment 
> 150,000 2000 
 
2000 
1998 
Less sensitive  
coastal waters 
Primary 
Normal* Secondary 
More sensitive Secondary and possible 
N&P reduction ** 
 15,000- 
150,000 
2000 
 
2000 
1998 
 
 
Less sensitive 
 coastal waters 
 
Primary 
Normal Secondary 
More sensitive Secondary and possible 
N&P reduction 
10,000- 
15,000 
2005 
 
2005 
1998 
 
Less sensitive  
coastal waters 
Primary 
Normal Secondary 
More sensitive Secondary and possible 
N&P reduction 
 
  2,000 
10,000 
2005 
 
2005 
2005 
 
 
Normal costal Appropriate*** 
Less sensitive 
estuaries 
Primary 
Other estuaries & 
freshwater 
 
Secondary 
< 2,000 2005 All receiving 
water 
Appropriate 
  *Normal: receiving water is categorized as neither less nor more sensitive, and there                                                                                                                     
are no detrimental effects on environment. **N&P: reducing nitrogen and phosphates. 
***Appropriate: any treatment allowing receiving water to meet quality objectives 
required. 
 
 
 
4.2.3 Disposal of treated wastewater  
All wastewater treatment plants must get a permit from local Environmental 
Protection Agencies (e.g. Environment Agency in England and Wales, Scottish 
Environment Protection Agency in Scotland, Northern Ireland Environment in 
North Ireland) in order to discharge effluent into the environment (Water UK 
2011). Generally, the treatment required for discharging final treated effluent to 
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the environment depends on the receiving waters and the population equivalent 
as shown in Table 4.1.  
 
4.2.4 Sewage sludge disposal  
Approximately 80% of sewage sludge is used as a soil enhancer and fertilizer 
on agricultural land. The quantity of sewage sludge used for this purpose is 
generally increasing in the UK as shown in Table 4.2 (Defra 2012). 
 
Table 4.2: Summary of Sewage sludge re-uses and disposal routes in  
the UK (Defra 2012) 
Reuse 
 
Sludge Reused 
(Tons dry solids) 
Sludge Disposed 
(Tons dry solids) 
Total 
 Soil & 
Agriculture 
Other Landfill Incineration Other  
1992 440137 32100 129748 89800 24300 997673 
2008 1241639 90845 10882 1858902 1523 1530779 
2010 1118159 23385 8787 259642 2863 1412836 
 
 
 
The disadvantage of sludge use in agriculture is that, some pharmaceutical 
compounds are adsorbed onto sludge during wastewater treatment and 
sometimes later released into the environment through the transportation of 
sludge particles and their application in agriculture (Clarke and Smith 2011). 
Chemicals discharged from industrial, domestic and urban sources into the 
urban wastewater collection system, are sometimes transferred to the residual 
sewage sludge during wastewater treatment. As stated previously in page 25, 
the anaerobic digestion process is used to treat sludge in the UK. Studies have 
shown that, norfloxacin, ofloxacin, ciprofloxacin, doxycycline, clotrimazole, 
ketoconazole and econazole compounds were detected in sludge samples at 
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less than 1 mg/kg dry weight (Lindberg et al. 2005; Golet et al. 2002). Clarke 
and Smith (2011) estimated the concentrations of pharmaceutical compounds 
in agricultural soils amended with biosolids to be less than1 mg/kg dry weight, 
which is significantly below the soil predicted no effect environmental 
concentration (PNEC) values. 
 
4.3 Wastewater management in Saudi Arabia 
Saudi Arabia is a hot and dry country located in an arid region where water 
resources are limited and the demand for water increases continuously. 
Ambient temperatures in Saudi Arabia during summer can range between 30oC 
and 55oC (Almazroui et al. 2012). In Saudi Arabia, it is not only households that 
consume clean water but also industry and agriculture. Reusing wastewater for 
agriculture and industry is a solution for the problem of limited water resources. 
However, wastewater needs to be treated at a high level before use. In Saudi 
Arabia, hospital wastewater is often pre-treated onsite in some cities without co-
treatment with municipal wastewater as reported in UK.   
This section provides an overview of the geography and climate of Saudi Arabia 
and an insight into its approach to water and wastewater treatment and 
management. Also, it reviews hospital wastewater management including 
collection, treatment and disposal strategies.  
 
4.3.1 Description of Saudi Arabia 
Saudi Arabia is located in South West Asia, it occupies the majority of the 
Arabian Peninsula, and is at the crossroads between Asia and Africa, with a 
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land area of 2,149,690 km2 (Figure 4.1). Saudi Arabia is the largest country on 
the Arabian Peninsula and extends from the Red Sea in the west to the Arabian 
Gulf in the east. The population was estimated in 2012 to be about 29,195,895, 
and the annual population growth rate is about 1.5% (MOH 2012).  
Riyadh is the capital and the largest city of Saudi Arabia. It is located in the 
centre of the country and is one of the 13 provinces of Saudi Arabia. Riyadh is a 
relatively warm city and classified as having a hot desert climate, with an 
average annual temperature of above 26ºC (Figure 4.2). During the summer 
months, the temperature is extremely hot, approaching 50°C occasionally. The 
annual rainfall in Riyadh is very low, especially in summer, with an average 8 
mm annually, while the average total rainfall in Saudi Arabia is no more than 60 
mm. The population of Riyadh is estimated at 7,309,966 inhabitants, occupying 
an area of 1,554 km². Riyadh is governed by the Riyadh Principality, which 
appoints the executive committee that runs the everyday management of the 
city. In Riyadh, there are about 60 government hospitals, 435 government 
general practitioners, 47 private hospitals and 720 private GPs (excluding 
dental clinics) (MOH 2012). The Ministry of Health (MOH) manages most of 
these hospitals. Some hospitals have on-site wastewater treatment plants while 
others are directly connected to municipal wastewater treatment plants.   
Currently, only about 37% of Saudi Arabia is covered by a sewerage system 
and the length of the network sewerage system in 2012 was about 25,791 km 
(MOWE, 2012). However, the country has set the target of achieving 100% 
coverage of sewerage establishment across the whole country by 2025 (KAUST 
2012). It is expected that, with the forecasted increasing population growth in 
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the country, wastewater generation is projected to increase, thereby 
necessitating the need for greater sewerage coverage. 
 
 
Fig. 4.1: Saudi Arabia map. Source (Gause 2011) 
 
 
 
 
 
Fig. 4.2: Average temperature in Riyadh city, Saudi Arabia (BBC 2014) 
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4.3.2 Conventional Wastewater Treatment in Saudi Arabia  
The total amount of drinking water supplied by the Ministry of Water & Electricity 
(MOWE) to all the cities of Saudi Arabia was estimated at 2,527 million m3 in 
2012, and the total flow of municipal wastewater collected in sewer networks 
and passed through wastewater treatment plants was about 1,257 million m3 in 
the same year, as shown in Table 4.3 (MOWE, 2012). This implies that the 
amount of treated municipal wastewater is equivalent to 50% of the total 
amount of municipal water delivered. Also, it is worth noting that not all urban 
water requirements are provided by MOWE. In many urban and rural areas, 
water supplies are provided from private sources, such as wells, other than 
those operated by MOWE. Another factor to be considered is the fact that part 
of the wastewater collected from urban areas is collected as a result of 
extensive infiltration to the sewer systems due to the rising water table (perched 
water) (Al-Rehaili 1997). 
 
Table 4.3: Total water and wastewater in 2012 in Saudi Arabia and  
Riyadh city (MOWE 2012)  
 Riyadh city Total in  Saudi 
Arabia 
Total water consumption  758 million m3  2527 million m3 
Average human consumption 
daily 
285 L/day    238 L/day 
Total wastewater production  n/a  2021 million m3  
Total wastewater treated  349 million m3  1257 million m3 
                      
 
The municipal wastewater disposal in city areas is accomplished by a mixture of 
sewers and septic tanks. In small towns and rural areas the disposal is limited 
to septic tanks only (Abu-Rizaiza 1999). By 2011, 70 wastewater treatment 
 72 
 
plants (WWTP) had been built in the cities of Saudi Arabia to treat the collected 
wastewater from the network for safe disposal or reuse (MOWE 2014). The 
level of wastewater treatment required (secondary and tertiary treatment) is 
dependent on the intended end use. Generally, all wastewater is required to be 
treated to at least secondary levels prior to reuse, producing varying degrees of 
purity. 
Secondary treatment usually encompasses the activated sludge process and 
clarifier in a conventional wastewater treatment plant. Tertiary treatments like 
sand filtration and disinfection by chlorination, or other processes, are required 
when water is reused for irrigation. The chlorination process has become 
necessary in most conventional WWTPs (secondary or tertiary treatment). This 
is due to the fact that the potential for human contact has increased and 
chlorination can assist the removal of pathogens. Some effluent from WWTPs is 
used for restricted and unrestricted irrigation, public parks, medians of roads 
and highways, etc. A wide range of pharmaceutical compounds has commonly 
been detected in wastewater effluents in the US and Europe, and they have 
also been detected in effluents from conventional WWTPs in Saudi Arabia 
(Shraim et al. 2012 and Alidina et al. (2014). A case study carried out on four 
municipal WWTPs in western Saudi Arabia found a high concentration of 
pharmaceutical compounds (up to 16 ug/L) observed in the effluents of non-
nitrifying biological treatment plants (Alidina et al. 2014). However, no study has 
investigated the occurrence and efficient removal of pharmaceuticals 
compounds in hospital wastewater within Saudi Arabia. 
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4.3.3 Water reuse in Saudi Arabia 
Middle Eastern and North African (MENA) countries, including Saudi Arabia, are 
located within arid and semi-arid regions, and contain only 1% of the world’s 
freshwater, making them the driest countries in the world (Qadir et al. 2010). 
The MENA countries suffer from harsh water shortages and have very few 
sources of natural freshwater. In Saudi Arabia, almost 83% of the fresh water is 
used in farming (Abderrahman 2001). Consequently, groundwater has been 
over-exploited during the last 30 years. In order to meet the growing demand for 
water in the agriculture sector, the use of reclaimed wastewater for agricultural 
irrigation in Saudi Arabia has increased from 123 million m3/year in 2006 to 225 
million m3/year in 2011 (MOWE 2012). Currently, Saudi Arabia intends to put in 
place new policy initiatives that will motivate people to put their trust in 
reclaimed wastewater, thus, guaranteeing a substantial percentage of the 
nation’s future water supply (Jacobsen et al. 2012). 
The Ministry of Water and Electricity (MOWE) together with the Ministry of 
Municipalities and Rural Affairs (MMRA) have relaxed their rules regarding 
wastewater reclamation in order to expedite these reforms (Al-Jasser 2011, 
cited from Aljassim 2013). Nevertheless, wastewater reclamation in Saudi 
Arabia is a relatively recent development and a large amount of the reclaimed 
water is released into the sea and dry rivers beds. The primary use of reclaimed 
wastewater was initially in landscaping. Later, reclaimed wastewater began to 
be used in irrigation.  On a pilot-scale level, the recycled water is used to 
replenish the groundwater and safeguard the aquifer reserves, taking into 
account the possible harmful effects it may have on the health of the public and 
the quality of the groundwater. Reclaimed wastewater has also been used for 
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irrigating trees (palm) and fodder crops. Table 4.4 shows the Saudi Arabian 
regulations for raw wastewater entering treatment networks and the reclaimed 
wastewater that is used for irrigation purposes (MOWE 2014).  
At present, treated wastewater is only being used for irrigation in specific 
development programs for crops such as wheat, fodder, orchards and palm 
trees. Bearing in mind that these irrigated crops create products that commonly 
serve as food for livestock as well as humans, it is crucial that the reused water 
is thoroughly treated before use. 
 
Table 4.4: Saudi Arabian regulation of wastewater distribution entering 
treatment networks and reclaimed wastewater for irrigation purposes (MOWE 
2014). 
  
 
pollutants 
 
 Unit 
Raw 
wastewater 
entering 
planta 
Reclaimed wastewater 
Restricted 
Irrigationb 
Unrestricted 
Irrigationc 
Physical parameters 
TSS mg/L 600          40 d      10 d   
TDS mg/L - 2500 2500 
pH - 6-9 6-8.4 6-8.4 
Turbidity NTU - 5 5 
Chemical parameters  
BOD5 
COD 
mg/L 
mg/L 
500 
1000 
         40d 
- 
              10d      
- 
TOC mg/L 400 - - 
TDS mg/L - 2500 2500 
NH4-N mg/L 80 5 5 
NO3-N mg/L - 10 10 
Biological parameters 
Faecal Coliform CFU/100 ml          -    1000d            2.2d    
a Raw wastewater: Indicative raw wastewater related to large communities and 
companies that are not covered by sewage networks.   
bRestricted Irrigation: Can irrigate all types of crops except vegetables, tuber crops, 
and any fruit can touch treated water.  
 c Unrestricted Irrigation: Can irrigate all types of crops without exception. 
 d  Monthly average should not be more than limit in table 
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4.4. Current hospital wastewater management situation in Riyadh city: a 
review 
4.4.1 Hospital wastewater collection  
There are three options that are used for hospital wastewater collection and 
treatment operating in Riyadh, as shown in Figure 4.3 (a-c): 
 On-site hospital wastewater treatment plant: The most common type of 
treatment, where wastewater generated from the hospital is treated 
within the hospital facility prior to discharge into the municipal wastewater 
sewer. Although this scenario is likely to be costly relative to other 
possible options, it is considered to be the best option in terms of hazard 
reduction from point source (hospital) as a consequence of the two stage 
treatment level and maximal safety (Pauwels and Verstraete 2006). 
 Municipal treatment: Alternatively, rather than onsite treatment, hospital 
wastewater can be directly connected to urban sewerage and co-treated 
in the municipal WWTP. This scenario is similar to hospital wastewater 
management in the UK. 
 Onsite collection: The hospital wastewater is collected into ground tanks 
located at the hospital facility. The raw wastewater is collected 
periodically for treatment at the central municipal WWTP. The third 
scenario is applied when the hospital is not covered by a sewerage 
system.  
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Fig. 4.3 (a-c): Scenarios of hospital wastewater treatment, management and 
disposal in Riyadh, Saudi Arabia. 
 
 
4.4.2 Hospital wastewater treatment  
Onsite hospital wastewater treatment processes include three or four stages:  
(1) Primary treatment to settle out larger suspended solids. 
(2)  Secondary treatment to reduce organic matter by biological treatment.  
(3) Tertiary treatment.  
(4) Chlorination process for disinfection.  
Onsite treatment plants are operated by the Ministry of Health under the control 
and monitoring of the Ministry of Water and Electricity in order to assess the 
quality of the effluent through regular sampling and analysis of pre-treated 
effluents. The effluent is normally discharged into the sewer system (via 
underground pipe) to Riyadh’s central WWTP.  
There are many WWTPs around Riyadh that serve the city. However, the 
largest WWTP, that receives the inflow of hospital wastewater, is the Riyadh 
central WWTP, shown schematically in Figure 4.4.  
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Fig. 4.4: Treatment schematics of a conventional wastewater treatment  
plant (Aljassim 2013) 
 
 
 
It has a capacity of about 600,000 m3/day and offers integrated advanced 
treatment, including preliminary treatment, primary treatment, secondary 
treatment (aeration tank) and tertiary treatment. Tertiary treatment is carried out 
using sand filtration and chlorination processes. The plant receives about 
500,000 to 550,000 m3 of wastewater daily (MOWE 2012).  The flow rate tends 
to be higher during the summer due to increases in municipal water use as a 
result of the relatively high temperature.  
 
4.4.3 Disposal of treated wastewater  
All wastewater treatment plants must get a permit from the Ministry of Water 
and Electricity in order to discharge their treated effluent.  The treatment plants 
are not allowed to discharge effluent to wells, dams and sources of drinking 
water (MOWE 2014). The effluent discharged must comply with minimum 
standards, as shown in Table 4.5 (MOWE 2012). The effluents from wastewater 
treatment plants can be used in irrigation, street cleaning and industrial 
applications. 
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Table 4.5: Maximum level of parameters permitted for discharge into 
the environment or system sewage (MOWE 2012). 
 
Parameter Maximum level 
TSS 40 mg/L 
pH 6-8.4 
BOD5 40 mg/L 
Turbidity 5 NTU 
phenols 0.002 mg/L 
Coliform 1000 cells /100 ml 
NO3-N 10 mg/L 
NH3-N 5 mg/L 
                                     
    
 
4.3 Conclusion  
The UK and Saudi Arabia apply two different hospital wastewater management 
practices.  A co-treatment with municipal wastewater is a common practice in 
the UK, while onsite treatment is common practice in Saudi Arabia. 
Furthermore, the treatment plants in both countries operate under different 
ambient temperature conditions. The next chapter will investigate the 
occurrence and performance of selected wastewater treatment plants in both 
countries in terms of removal of pharmaceutical compounds.   
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CHAPTER 5 
Identification of key factors affecting pharmaceutical 
compounds removal in biological treatment under different 
environmental conditions 
5.1 Introduction  
The activated sludge process (ASP) is the most commonly used process in 
many municipal wastewater treatment plants (MWWTPs). The principal aim of 
ASP is to break down organic matter into carbon dioxide, water, and other 
inorganic compounds under aerobic conditions. A parameter commonly used 
for wastewater treatment design is the solid retention time (SRT) (Clara et al. 
2005a; Fernandez-Fontaina et al. 2012). The SRT is related to the time of 
residence and growth rates of the microorganisms in the reactor that are able to 
reproduce during this time (Clara et al. 2005a). The maximum growth rates of 
microorganisms also depends on the temperature, where high temperatures 
enhance microbial activity and might be preferable for more effective removal 
(LaPara et al. 2000; Vieno et al. 2005; Massmann et al. 2006). The SRT, 
temperature and others factors, including the hydraulic retention time (HRT) 
(also known as the aeration time) and pH, have important effects on the 
development of slow-growth microorganisms, which subsequently influence the 
development of a high diversity of microorganisms in the reactors (Calderón et 
al. 2013). Microorganisms usually reach their optimal activity at warm 
temperatures of between 20 and 40°C (Kaleli and Islam 1997). The effects of 
temperature during the ASP have mainly been considered in studies that have 
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examined the microbial communities in laboratory experiments (Ahn and Logan 
2010; Kaleli and Islam 1997) and have assessed seasonal variation (Calderón 
et al. 2013).   
In this study, the fate of pharmaceutical compounds at four UK MWWTPs and 
two Saudi Arabian hospital WWTPs (HWWTPs) were assessed and considered 
in terms of the operational parameters employed under different environmental 
conditions: temperate climate (UK) and tropical climate (Saudi Arabia).  The 
sampling regime and analytical methods employed in carrying out this study 
have been explained in Chapter 3. 
 
5.2 Results and discussion 
5.2.1 UK municipal wastewater treatment plants 
5.2.1.1 Conventional parameters 
The averages of the conventional parameters measured in the influent and 
effluent samples generally show high removal efficiencies in each MWWTP in 
the UK (Table 5.1) were measured. The average concentrations of BOD5, COD 
and TOC measured in the influents varied widely from plant to plant, being 45–
191, 113–419 and 44–135 mg/L, respectively. The average concentrations of 
these parameters in the effluent were much lower, with BOD5, COD and TOC 
ranges of 4–7, 19–30 and 7–10 mg/L, respectively (Table 5.1). 
The Cupar, Guardbridge and Hatton plants (which use ASP) appeared to be 
much more efficient at removing organic matter than the Letham plant, which 
uses a TF. 
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Table 5.1: Influent and effluent concentrations of conventional parameters 
measured at municipal wastewater treatment plants in the UK. 
 Letham (TF) Cupar (ASP) Guardbridge (ASP) Hatton (ASP) 
Inf. 
(mg/L) 
Eff. 
(mg/L) 
RE 
(%) 
Inf. 
(mg/L) 
Eff. 
(mg/L) 
RE 
(%) 
Inf. 
(mg/L) 
Eff. 
(mg/L) 
RE 
(%) 
Inf. 
(mg/L) 
Eff. 
(mg/L) 
RE 
(%) 
BOD5 45±17   7±2 84 191±45   5±3 97   65±23   6±2 91   54±23   4±2 93 
COD 117±38  30±6 74 419±114 22±5 95 150±46 19±6 87 113±42 23±4 80 
TOC 44±13 10±3 77 135±46   7±2 95   52±29 10±3 81   49±18   8±2 84 
NO3   13±9      51±16 -     3±3 34±8 -     9±7 61±16 -     1±2   1±2 - 
NH4   11±6   0.7±0.7 94   24±11  0.3±0.5 99   21±10 0.1±0.2 100   22±7 19±6 14 
Results are reported as mean ± standard deviation; Inf: Influent; Eff: Effluent; RE: 
Removal Efficiency; ASP: Activated Sludge Plant; TF: Trickling Filter Plant. 
 
The performance of the nitrification processes in the Letham, Cupar and 
Guardbridge plants were efficient (they measured 94%, 99% and 100% 
removal efficiency, respectively), while in the Hatton plant there was no 
significant change in ammonium concentrations (Table 5.1). Elevated ammonia 
concentrations of 13–30 mg/L were observed in the effluent of the Hatton plant, 
while low average ammonia concentrations (<0.3 mg/L) were observed for both 
the effluent from the Cupar and Guardbridge MWWTPs. Nitrate concentrations 
for Cupar and Guardbridge plants varied between 18 and 75 mg/L confirming 
efficient biological ammonia removal. 
In general, the removal efficiency of organic compounds (BOD5, COD and 
TOC) was higher in the ASP than in the TF. In terms of the nitrifying conditions, 
the Cupar, Guardbridge and Letham plants were observed to be efficient, while 
poor nitrification processes were found to have occurred at Hatton. Based on 
the observations, the poor nitrification process is likely to be attributable to an 
insufficient aeration time.  
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5.2.1.2 Pharmaceutical compounds  
Table 5.2 shows the concentrations of selected compounds in both influent and 
effluent samples from the four UK MWWTPs. Of the fifteen pharmaceuticals 
analysed in the wastewater samples, eight compounds were detected: 
antibiotics (sulfamethoxazole and its metabolite, N-acetyl-sulfamethoxazole), 
two analgesics (naproxen and paracetamol), one β-blocker (atenolol), one 
anaesthetic (lidocaine), one antidepressant (carbamazepine) and one lipid 
regulator (bezafibrate). One compound was detected but could not be 
quantified (clarithromycin), and the other compounds analysed including 
ibuprofen, ciprofloxacin, diatrizoate, iopamidol, cyclophosphamide and 
ifosfamide were not detected in the samples. 
A high variation in the concentrations of the compounds examined was 
observed across the MWWTPs. This variation may have arisen due to various 
different factors such as consumption, excretion or uncertainty arising from the 
sampling methods. Uncertainty related to sampling may influence data 
accuracy in that the uncertainly may be due to the varied sampling times 
employed as discussed in Chapter 3 (page 53). In addition, the potential 
adsorption of pharmaceutical compounds onto sludge (this aspect was not 
investigated in the study) during the treatment processes can also influence the 
data accuracy between influent and effluent. 
The results showed that the Hatton plant had relatively high concentrations of 
pharmaceutical compounds in the raw wastewater. This is likely to be because 
the plant receives wastewater from many hospitals, unlike the other three plants 
(see Table 3.3), which is likely to contribute to high levels of pharmaceutical 
compounds in the resulting wastewater. 
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Table 5.2: Concentrations of pharmaceutical compounds in selected 
municipal wastewater treatment plants in the UK. 
 
 
 
 
 
LOQ 
ng/L 
Hatton Cupar Letham Guardbridge 
 
Class 
 
Compound 
 
  Inf. 
 (ng/L) 
  Eff. 
 (ng/L) 
Inf. 
(ng/L) 
Eff. 
(ng/L) 
Inf. 
(ng/L) 
 Eff. 
 (ng/L) 
Inf. 
(ng/L) 
 Eff. 
 (ng/L) 
 
Analgesics and 
Anti-inflamma- 
tories 
 
Paracetamol 
 
100 
 
7290 
 
n/d 
 
5248 
 
n/d 
 
3701 
 
1068 
 
3574 
 
n/d 
 
Naproxen 
 
200 
 
2106 
 
575 
 
1023 
 
<LOQ 
 
n/d 
 
n/d 
 
2441 
 
n/d 
 
Ibuprofen 
 
1000 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
Antidepressants 
 
Carbamazepine 
 
80 
 
 657 
 
951 
 
567 
 
926 
 
<LOQ 
 
- 
 
653 
 
856 
 
β-blockers 
 
Atenolol 
 
80 
 
 384 
 
149 
 
601 
 
< LOQ 
 
301 
 
149 
 
159 
 
103 
 
Lipid Regulators 
 
Bezafibrate 
 
200 
 
1221 
 
1121 
 
494 
 
232 
 
n/d 
 
n/d 
 
1852 
 
369 
 
Anaesthetics 
 
Lidocaine 
 
80 
 
 193 
 
217 
 
n/d 
 
206 
 
n/d 
 
n/d 
 
n/d 
 
148 
 
Antibiotics 
 
Ciprofloxacin 
 
400 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
 
 
Clarithromycin 
 
200 
 
n/d 
 
<LOQ 
 
n/d 
 
<LOQ 
 
n/d 
 
<LOQ 
 
n/d 
 
<LOQ 
 
Sulfamethoxazo. 
 
80 
 
 n/d  
 
132 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
Metabolite of 
sulfamethoxazo. 
 
NACS 
 
200 
 
 401 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
Contrast Media 
 
Diatrizoate 
 
400 
 
 n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
Iopamidol 
 
400 
 
 n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
Cytostatics 
 
Cyclophospham. 
 
200 
 
 n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
Ifosfamide 
 
80 
 
 n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
Inf = influent; Eff = effluent; Sampling period: 3.10.2012–9.11.2012 and 3.6.2013–
28.6.2013 twice weekly (n = 1, composite samples made from the samples taken 
during both periods); LOQ = limit of quantitation (substances detected but not 
quantifiable); n/d = not detected. 
 
Of the compounds that were detected in the influent samples, the 
concentrations of the over-counter drugs, paracetamol and naproxen, were 
highest from 3701 ng/L to 7290 ng/L for paracetamol and up to 2441 ng/L for 
naproxen. Bezafibrate was also detected at a concentration of 1852 ng/L in the 
raw influent of the Guardbridge plant. Hatton influent had the highest 
paracetamol concentration (7292 ng/L) and Guardbridge influent had the 
highest naproxen and bezafibrate concentrations at 2441 ng/L and 1852 ng/L, 
respectively. The concentrations of naproxen and bezafibrate in the influent 
samples were similar to results reported in the literature. For example, 
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Kasprzyk-Hordern et al. (2009b) reported naproxen concentrations of 510–2480 
ng/L in the influents of two MWWTPs in Wales and concentrations of 
bezafibrate were measured at around 2000 ng/L by Miege et al. (2009). 
Furthermore, higher concentrations of paracetamol than those recorded in this 
study, of up to 180 µg/L, have also been detected in Spanish MWWTPs 
(Radjenovic et al. 2009) and Welsh MWWTPs (Kasprzyk-Hordern et al. 2009b).   
Lower concentrations of paracetamol, naproxen and bezafibrate were observed 
in the WWTP effluents, with maximum removal efficiencies of > 99% for 
paracetamol and naproxen (Figure 5.1). The removal efficiencies of the 
compounds varied between the MWWTPs. An almost complete removal of 
paracetamol and naproxen was achieved in the Guardbridge and Cupar plants, 
while the removal efficiency of naproxen in the Hatton plant was about 73%. 
The removal efficiencies of bezafibrate among the MWWTPs ranged from 8% 
(Hatton) to 80% (Guardbridge).  
 
 
Fig. 5.1: Removal efficiencies of pharmaceutical compounds in municipal 
wastewater treatment plants in the UK. 
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Carbamazepine was detected in most of the MWWTP samples in this study. It 
did not exhibit large variations in concentration between the influents and 
effluents of the MWWTPs (567–926 ng/L). Removal of the compound was poor 
in all WWTPs, with higher concentrations (31- 63% higher) measured in the 
effluents than the influents at each ASP. Carbamazepine has been reported as 
recalcitrant to biological treatment processes and, thus, poor removal 
efficiencies have been found in respect of conventional biological treatment and 
membrane bioreactor (MBR) treatments (Jelic et al. 2012b; Rua-Gomez and 
Puttmann 2012). In addition, the compound has frequently been detected in 
WWTP effluents and river samples from European and North American waters 
by prior research studies (Ternes 1998; Heberer 2002; Metcalfe et al. 2003 and 
Miao et al. 2005). The carbamazepine results from this study are consistent 
with those presented in previous research, where carbamazepine 
concentrations in effluent samples were found to be 20–100% higher than in 
influent samples (Joss et al. 2005; Clara et al. 2005a and Vieno et al. 2007). 
The increases in carbamazepine concentrations may be attributed to its 
metabolic chemical properties. Carbamazepine is excreted from humans in the 
form of carbamazepine itself or as its metabolites, but during wastewater 
treatment processes the metabolites can be converted back to the parent 
compound through enzymatic processes (Vieno et al. 2007; Leclercq et al. 
2009).  
Atenolol was also found in most of the influents and effluents of the MWWTPs 
sampled in this study. The Cupar plant had the highest influent concentration, 
of 601 ng/L, while Guardbridge had the lowest influent concentration, at a level 
of 160 ng/L. In the effluents of the MWWTPs, the concentrations of atenolol 
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were found to be much lower, between 149 ng/L (Hatton) and at a 
concentration less than the limit of quantitation (LOQ) in the Cupar MWWTP. 
Lidocaine was detected in most of the effluents of the MWWTPs, with 
concentrations ranging between 148 and 217 ng/L, but it was only detected in 
the influent samples of the Hatton plant. This discrepancy may be related to the 
metabolism processes, or to the instability of the compound (Rua-Gomez and 
Puttmann 2012). Lidocaine can be metabolized to monoethylglycinexylidide 
(MEGX) in humans (Tam et al. 1990). MEGX can further metabolize to 2,6-
dimethylaniline (2,6-DMA) (Bangoluri et al. 2005). However, some metabolites 
can be converted back to their parent form during treatment processes 
(Watkinson et al. 2007). Therefore, it is possible that metabolites of lidocaine 
might be converted back to the parent compound. Rua-Gomez and Puttmann 
(2012) reported similar concentrations of lidocaine in Germany’s WWTPs, 
ranging between 91 and 217 ng/L.  
With regard to the antibiotics, while detected in the effluents, the concentrations 
of clarithromycin were found to be <LOQ. In contrast, concentrations of 
sulfamethoxazole and its metabolite, N-acetyl-sulfamethoxazole (NACS), were 
detected in the effluent and influent of the Hatton plant, respectively. 
Sulfamethoxazole was found at a relatively low concentration in the effluent 
(132 ng/L), while NACS was present at a higher concentration (402 ng/L). 
Normally, 50% of sulfamethoxazole is metabolized to NACS in the human body, 
while the residue remains unchanged (Gobel et al. 2005). During biological 
wastewater treatment processes, NACS can be converted back to its parent 
compound (Gobel et al. 2005; Gobel et al. 2007; Shelver et al. 2008). This may 
explain why NACS was detected in the influent and sulfamethoxazole was 
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found in the effluent. Ashton et al. (2004) reported similar results, in which 
NACS was observed at higher concentrations (33%) relative to 
sulfamethoxazole in the UK WWTPs. 
 
5.2.1.3 Potential influences of the operational parameters on 
removal efficiencies 
The removal efficiencies of the pharmaceutical compounds detected in the 
wastewater samples (Figure 5.1; Table 5.2), are discussed in this section in 
relation to the type of biological treatment and operational parameters 
employed. It is worth noting that only the elimination from the liquid phase was 
investigated in this study, and that it is possible that some of the micropollutants 
could have been adsorbed onto the sludge as reported in the Chapter 3. 
 
 Paracetamol 
Paracetamol was removed efficiently by all four of the MWWTPs. The 
MWWTPs that employed ASP (Hatton, Cupar and Guardbridge) achieved 
greater than 99% removal efficiencies, while 71% removal efficiency was 
observed in the Letham plant (which uses TF). These results correspond with 
those of Kasprzyk-Hordern et al. (2009b) and Verlicchi et al. (2013), who 
reported that ASP can achieve 99% removal efficiency for paracetamol. Overall, 
paracetamol was removed efficiently by the different MWWTPs using both 
processes (ASP and TF) under conventional operational parameters.  
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 Naproxen 
The average removal efficiency of naproxen by the Guardbridge, Cupar and 
Hatton MWWTPs was 91%. The highest removal efficiencies of naproxen, 
which reached levels of over 99%, were observed in the Guardbridge and 
Cupar plants (nitrifying ASP), while the Hatton plant (non-nitrifying ASP) only 
achieved 73% removal efficiency (Figure 5.1). The high effectiveness of the 
nitrification processes during the biological treatment may be correlated with the 
HRTs which are longer in the Guardbridge and Cupar MWWTPs.  From Table 
3.2, the average operational HRTs for Cupar, Guardbridge and Hatton 
MWWTPs were 16, 17 and 4 hours respectively. Therefore, longer HRTs may 
have enhanced the biodegradation of naproxen at the Cupar and Guardbridge 
MWWTPs. Increases in the SRTs and HRTs can enhance bacterial growth and 
the establishment of diverse communities that have a greater capacity and 
potential for removing micropollutants (Kreuzinger et al. 2004). The results from 
this study compare favourably with the average removal efficiencies of 81% 
measured in six Taiwan WWTPs (Lin et al. 2010) and of 80% in WWTPs from 
five EU countries (Paxeus 2004). Lower average removal efficiencies of 
naproxen were also reported at several WWTPs, including 66% in Germany 
(Ternes 1998), 40–55% in Spain (Carballa et al. 2004) and 45% in Japan 
(Nakada et al. 2006). 
 
 Bezafibrate 
The removal efficiencies of bezafibrate varied across the MWWTPs, with an 
average of less than 50%; however, the removal efficiencies in the MWWTPs 
that used longer SRT and HRT were much higher (53–80%) than in the non-
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nitrifying ASP (8%). Miege et al. (2009) and Kasprzyk-Hordern et al. (2009b) 
reported bezafibrate removal efficiencies of 60–70% during ASP. Furthermore, 
Castiglioni et al. (2006) reported that bezafibrate removal during ASP was 
variable and dependent on the season (they measured 15% and 87% removal 
efficiencies in winter and summer respectively). In this study, the higher 
bezafibrate removal efficiency obtained in the Cupar and Guardbridge 
MWWTPs was also likely to have been linked to their higher HRTs, when 
compared to the Hatton MWWTP.  
 
 Atenolol 
The average removal of atenolol among the four WWTPs was 62%. One of the 
nitrifying ASP (Cupar) was the most efficient at removal (> 99%), while the non-
nitrifying ASP (Hatton) achieved a removal efficiency of 61%. The TF (Letham) 
only removed 50% of the atenolol. A recent study by Kasprzyk-Hordern et al. 
(2009b) found similar removal efficiency for atenolol in ASP (80%), when 
compared to TF processes (70%). It seems that atenolol is highly 
biodegradable, particularly in ASP with long HRTs.  
 
 Lidocaine 
Lidocaine was detected in the effluents (at levels of up to 260 ng/L) of the three 
ASPs, but only in the influent at Hatton MWWTPs and for Cupar and 
Guardbridge MWWTPs exhibited high negative removal efficiency for this 
reason (Figure 5.1).  Consequently, removal efficiencies could not be 
calculated. Rúa-Gómez and Püttmann (2012) reported that lidocaine was only 
partially removed through different WWTPs. The concentrations detected in the 
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effluents of this study were below the PNEC available from the literature (82 
µg/L, Verlicchi et al. 2012a); therefore, it is assumed no immediate risk was 
being posed to aquatic organisms. Nevertheless, the continuous discharge of 
lidocaine into receiving waters may lead to its accumulation, which could have 
long-term effects. 
 
 Carbamazepine 
As discussed above, carbamazepine concentration was found to have 
increased by up to 63% in the effluents when compared to the influents. This 
indicates that the ASPs may be ineffective at removing the compound for the 
range of SRT and HRT that the selected plants were operating at during the 
sampling period. Kasprzyk-Hordern et al. (2009b) also observed poor removal 
efficiencies of carbamazepine in ASPs in Wales. The range of carbamazepine 
removal efficiencies by MWWTPs, based on 19 published studies, averaged 
below 10% (Zhang et al. 2008). The widespread detection of carbamazepine in 
the environment may be related to its high persistence during conventional 
treatments at MWWTPs, where it is believed to neither degrade nor adsorb onto 
sludge (Clara et al. 2004). The concentrations detected in the effluents in this 
study (up to 951 ng/L) were below the PNEC available from the literature (13.8 
µg/L, Verlicchi et al. 2012a). However, the continuous discharge of this 
compound to receiving waters may build up to levels of concentration that are 
toxic to aquatic organisms.  
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 Sulfamethoxazole and its metabolites (NACS) 
Sulfamethoxazole was the only antibiotic detected in the effluent of the Hatton 
plant. Consequently, removal efficiencies could not be calculated and a high 
negative is shown in figure 5.1. NACS may have been removed or converted 
back to its parent compound (sulfamethoxazole) during treatment, as discussed 
above (page 86).  
 
5.2.1.4 Discussion of the importance of key factors on removal 
efficiency 
 
In MWWTPs, the elimination of pharmaceuticals is affected by many factors, 
such as temperature, SRT, HRT and the level of dilution (Kasprzyk-Hordern et 
al. 2009b; Verlicchi et al. 2012a). In this study, the samples collected during 
winter and summer were mixed together; therefore, the effect of temperature on 
the removal of the compounds cannot be assessed. However, the other factors 
are discussed below.  
 
 HRT  
Activated sludge processes, which employed longer HRTs in this study, were 
found to enhance the biodegradation rates of some compounds. These 
increases in removal efficiencies were likely due to the longer available 
adaption and development period for certain microbial communities that are 
able to break down pharmaceuticals (Falas et al. 2012; Clara et al.  2005a). For 
example, the Guardbridge and Cupar MWWTPs used longer HRTs and 
achieved more effective removal of some compounds (e.g., naproxen, 
 92 
 
bezafibrate and atenolol), in comparison to the Hatton MWWTP, which had a 
poor nitrifying process and a shorter HRT. Hence, effective nitrification can be 
used as an indicator of the length of biodegradation times. That is, the longer 
the HRT the greater the potential for effective nitrification, and the longer the 
period for microbial adaptation and biodegradation of pharmaceutical 
compounds. These results are in accordance with those of other studies 
(Fernandez-Fontaina et al. 2012; Clara et al. 2005a; Estrada-Arriaga et al. 
2011), which reported positive correlations between the removal rates of 
several pharmaceuticals and the SRT and/or HRT. 
 
 Dilution of wastewater  
The dilution factor, for example by heavy rainfall or high flow rates, may reduce 
the influent concentrations and may also deteriorate the removal efficiencies of 
pharmaceutical compounds (Helwig et al. 2013; Joss et al. 2006). Also, the 
entry of excess water may reduce the HRT in the treatment plant (Vienoa et al. 
2007; Vienoa et al. 2005). The deterioration of removal efficiencies in these 
situations has been linked to decreases in the biodegradation rates of the 
pharmaceuticals (Joss et al. 2006). In this study, a period of heavy rain 
occurred during the sampling period in winter, especially in Hatton area. This 
might have caused a decrease in the HRT used by the MWWTP (data not 
available). Therefore, the concentrations of compounds in the samples from this 
period and their removal efficiencies may have been influenced by the dilution 
factor. However, the effects of dilution would have also reduced the possible 
environmental hazards posed by the compounds to aquatic organisms, 
especially in terms of the acute toxicity or chronic effects (Gros et al. 20101). 
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5.2.2 Saudi Arabia hospital wastewater treatment plants 
5.2.2.1 Conventional parameters 
Table 5.3 summarises the average concentrations of conventional parameters 
for the influent and effluent samples from both of the hospitals chosen in this 
study. The average concentrations of COD and nutrients in the influents of the 
HWWTPs were found to be similar. The average COD observed in the influents 
of the Salman HWWTP (SHWWTP) and the Imam HWWTP (IHWWTP) were 
376 and 336 mg/L, respectively. The COD in the effluents were much lower, at 
64 and 27 mg/L, respectively. However, the COD of the effluent from the 
SHWWTP was relatively higher than the COD limit values of restricted irrigation 
in Saudi Arabia (Chapter 4; Table 4.4) as set out in (MOWE 2014).  
 
Table 5.3: Influent and effluent concentrations of conventional parameters 
measured at hospital wastewater treatment plants in Saudi Arabia. 
 
Parameters  SHWWTP  IHWWTP 
Process 
technology 
Aerobic  Aerobic 
Ambient 
temperature (ºC) 
28±7  28±7 
pH                                       7.0-7.5   6.8-7.5 
 Inf. 
(mg/L) 
Eff. 
(mg/L) 
RE 
(%) 
Inf. 
(mg/L) 
Eff. 
(mg/L) 
RE 
(%) 
COD       376  64 83 336    27    92 
NH4    22.3   0.26 99   18.97 0  100 
NO2        0.30   0.61 -     0.33      0.25 - 
NO3        0.23   0.67 -     0.35      2.43 - 
SHWWTP = Salman hospital wastewater treatment plant; IHWWTP = Imam hospital 
wastewater treatment plant; ER= Removal Efficiency 
 
 
The performance of the nitrification process in both HWWTPs was observed to 
be efficient (Table 5.3); the average ammonia concentrations observed in the 
effluents from both HWWTPs were less than 0.3 mg/L. Data on the HRTs or 
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SRTs were not available, but highly efficient nitrification processes may be 
influenced by the high temperatures in Saudi Arabia, as normally, the activity of 
nitrifying bacteria increases with temperature (Kaleli and Islam 1997). The low 
concentrations of nitrate in the effluents, despite the almost 100% removal of 
influent ammonia suggests that the operational methods of the plants might 
have encouraged significant denitrification (i.e., nitrate conversion to nitrogen 
gas) to occur. It is therefore assumed, in the interpretation of the results, that 
the plants were operated at HRT and SRT values that enabled effective 
nitrification to take place. 
 
5.2.2.2 Pharmaceutical compounds  
Table 5.4 summarises the mean concentrations of the selected compounds in 
the influent and effluent samples obtained from the two hospital wastewater 
treatment plants (HWWTPs). Nine pharmaceutical compounds were detected 
out of the twelve compounds analysed, which included four antibiotic 
compounds (ciprofloxacin, clarithromycin, sulfamethoxazole, and its metabolite 
NACS), one analgesic (paracetamol), one stimulant (caffeine), one β-blocker 
(atenolol), one anaesthetic (lidocaine) and one antidepressant 
(carbamazepine). The other compounds tested for, including bezafibrate, 
erythromycin and cyclophosphamide, were not detected in either the influents 
or effluents of the HWWTPs. Caffeine and paracetamol were detected in all the 
influent samples and were present at the highest concentrations of all the 
compounds analysed, at 25828–91593 ng/L and 12008–12673 ng/L, 
respectively. Especially high concentrations of caffeine (> 90 µg/L) were found 
at the SHWWTP influent. Caffeine has been detected in MWWTPs around the 
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world ranging from 3.4–6.6 µg/L in China (Sui et al. 2010), to 7–73 µg/L in 
Swiss MWWTPs (Buerge et al. 2003) and at concentrations up to 89 µg/L in 
Spanish MWWTPs (Martín et al. 2012). 
 
Table 5.4: Concentrations of pharmaceutical compounds in hospital 
wastewater treatment plants in Saudi Arabia (ng/L) 
 
Class Compound LOQ SHWWTP 
Inf. 
SHWWTP 
Eff. 
IHWWTP 
Inf. 
IHWWTP 
Eff. 
Analgesics  Paracetamol 0.5 12390±343  73±11 12303±177 157±20 
 
Antidepressant 
 
Carbamazepine 
 
  0.25 
 
    151±13 
 
     41±1 
 
     73±14.3 
 
n/d 
 
β-blockers 
 
Atenolol 
 
5.0 
 
    728±82 
 
     46±2 
 
   329±27.9 
 
   55±3.6 
 
Lipid  
 
Bezafibrate 
 
0.1 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
Anaesthetics 
 
Lidocaine 
 
1.0 
 
    158±12 
 
   114±4 
 
    129±6 
 
<LOQ 
 
Antibiotics 
 
Ciprofloxacin 
 
2.5 
 
  5611±657 
 
n/d 
 
2183±251 
 
n/d 
 
Clarithromycin 
 
0.5 
 
83±72 
 
     22±9 
 
38.0 
 
n/d 
 
Sulfamethoxazol 
 
1.0 
 
      30±7 
 
n/d 
 
    132±5 
 
n/d 
 
Erythromycin 
 
0.5 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
Metabolite of 
sulfamethoxaz. 
 
NACS 
 
5.0 
 
  1234±55 
 
  59±14 
 
506±21 
 
n/d 
 
Cytostatic 
 
 
Cyclophosphamide 
 
 
1.0 
 
n/d 
 
n/d 
 
n/d 
 
n/d 
 
Others  Caffeine 2.5 74794±15502 n/d 27469±2018 n/d 
Results are reported as mean ± standard deviation (n= 3); LOQ = limit of quantitation 
(substances detected but not quantifiable); n/d = not detected.  
 
The high concentrations of caffeine observed in this study may be related to its 
administration along with other medication in order to enhance the effects of 
certain analgesics in cough, cold, and headache medicines (Lin et al. 2010; 
Weigel et al. 2002). It is also used as a cardiac, cerebral and respiratory 
stimulant and as a diuretic (Buerge et al. 2003). Both caffeine and paracetamol 
were almost completely removed from both of the HWWTPs. Negligible 
concentrations of paracetamol were detected in the HWWTP effluents, while 
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the removal efficiencies for caffeine were near 100%. Alidina et al. (2014) 
reported high concentrations of caffeine (64–16500 ng/L) in the effluent of six 
Saudi MWWTPs (but no data were available for influent concentrations in their 
study). 
As expected, the hospital influents were found to be significant sources of 
antibiotics in this study, and four of the antibiotic compounds examined 
(ciprofloxacin, clarithromycin, sulfamethoxazole and NACS) were detected at 
concentrations ranging from 30 to 5611 ng/L in the influents of the HWWTPs. 
The high concentration of the antibiotics in the raw HWW is likely to be due to 
the high levels of antibiotic consumption in hospitals (Kümmerere 2009). 
Ciprofloxacin was present in both influents at the highest concentrations of the 
antibiotic compounds tested, followed by NACS (a metabolite of 
sulfamethoxazole), with ranges of 2017–6105 ng/L and 483–1288 ng/L, 
respectively. Relatively low concentrations (<160 ng/L) of sulfamethoxazole and 
clarithromycin were detected in the raw HWW. It has previously been reported 
that high concentrations of antibiotics in effluents are of particular concern due 
to the potential for genotoxic effects and the development of antibiotic 
resistance in the environment (Brown et al. 2006). The spread of antibiotic 
resistance is a major threat to public health (Rogues et al. 2004; Vander 
Stichele et al. 2006). Previous studies have also found high concentrations of 
sulfamethoxazole (730 ng/L) in Saudi effluents from MWWTPs (Alidina et al. 
2014). However, in this study the concentrations of all the antibiotics in the 
effluents of the HWWTPs were found to be negligible, and lower than their 
respective PNECs reported in the literature (Verlicchi et al. 2012a). 
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Atenolol, carbamazepine and lidocaine concentrations were consistently 
detected in the influent samples of the HWWTPs at relatively low 
concentrations, of 304–824, 64–160 and 122–166 ng/L, respectively. 
Previously, atenolol was detected at low concentrations (1–4 ng/L) in the 
influent of a Saudi MWWTP (Shraim et al. 2012). These drugs are relatively 
recalcitrant to biological treatment and are generally only partially removed in 
wastewater treatment systems. In this study, negligible concentrations of these 
drugs were detected in the effluents of the HWWTPs, at 44–58 ng/L, up to 41 
ng/L and up to 118 ng/L, for atenolol, carbamazepine and lidocaine, 
respectively. These concentrations are lower than their respective PNECs 
(Verlicchi et al. 2012a). It should be noted, though, that a previous study has 
reported higher concentrations of atenolol (15–2550 ng/L) and carbamazepine 
(57–1200 ng/L) in the effluents of various MWWTPs in Saudi Arabia (Alidina et 
al. 2014). 
 
5.2.2.3 Potential influence of the operational parameters on removal 
efficiencies 
The removal efficiencies of pharmaceutical compounds from the HWW samples 
show that, on average, the most efficiently removed compounds were 
ciprofloxacin, caffeine, sulfamethoxazole, paracetamol and NACS (> 95%), 
followed by atenolol, carbamazepine and clarithromycin (> 85%) (Figure 5.2). 
The average removal efficiency of lidocaine was measured as greater than 65% 
at the two HWWTPs.  
 
 98 
 
 
Fig. 5.2: Removal efficiencies of pharmaceutical compounds at the hospital 
wastewater treatment plants in Saudi Arabia. Results shown are mean ± 
standard deviation (n = 3). 
 
 
 
 Paracetamol and caffeine  
 
Caffeine and paracetamol were both almost completely removed from each of 
the HWWTPs. The average removal efficiency of paracetamol was greater than 
98%, while for caffeine it was completely (100%) removed by both HWWTPs. 
Similar results were obtained for the removal of paracetamol (up to 99%) in 
ASP as found by Kasprzyk-Hordern et al. (2009b) and by Verlicchi et al. (2013), 
under temperate climate conditions. Thus, paracetamol removal at WWTPs 
seems possible with conventional ASP under different climate conditions (in 
both cold and warm weather). With regard to the removal of caffeine, Lin et al. 
(2010) reported similar caffeine removal efficiencies (99%) in six WWTPs in 
Taiwan. However, in contrast to these results, Buerge et al. (2003) found that 
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the removal efficiencies of caffeine varied (81–99%) at 13 Swiss MWWTPs. 
The authors indicated that the MWWTPs that were less efficient at removing 
caffeine (81%) had lower adaptation times for the microorganisms in the AS 
system (< 5 days versus > 5 days). As mentioned before, bacterial adaptation 
in ASP is enhanced through longer SRTs and higher temperatures (Batt et al. 
2006). Therefore, the high ambient temperatures and the possibility that both 
plants may have been operated at HRTs and SRTs that encouraged effective 
nitrification may have provided the conditions the enabled the effective 
biodegradation of both compounds.  
 
 Antibiotics  
The mean removal efficiencies of ciprofloxacin, clarithromycin, 
sulfamethoxazole and NACS at the SHWWTP were 100%, 87%, 100% and 
98%, respectively. The IHWWTP achieved 100% removal of all the antibiotics. 
Lin et al. (2009) previously studied sulfamethoxazole and clarithromycin, and 
reported that the removal efficiencies of six different WWTPs in Taiwan were 
greater than 50% and 20%, respectively. Carballa et al. (2004) also found a 
lower level of removal efficiency (< 60%) of sulfamethoxazole in ASP under 
temperate climate conditions (Galicia, Spain). A seasonal variation in the 
removal of sulfamethoxazole was observed, with a higher removal rate in 
summer (71%) than that which was observed in winter (17%) in Italy (Castiglioni 
et al. 2006). These results are much lower than the results observed in this 
study. Other studies indicated that re-conjugation of its metabolite (NACS), and 
thus higher concentrations of sulfamethoxazole occur in effluent compared to 
influent (Gobel et al. 2007; Shelver et al. 2008; Ashton et al. (2004). In this 
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study high removal efficiencies (> 98%) of both sulfamethoxazole and NACS 
were observed under tropical climate conditions and no concentrations of 
sulfamethoxazole were detected in the effluent samples. Consequently, no 
concentrations of NACS were left to re-conjugate to parent compounds as had 
been observed in the UK samples (page 86).   
The other antibiotic (ciprofloxacin) was also completely removed (100%) in both 
HWWTPs. Gao et al. (2012) reported a lower removal efficiency (67%) in a 
Chinese ASP. Ciprofloxacin is a fluoroquinolone and it is known that adsorption 
to sludge is a major removal process. For example, a significant amount of 
ciprofloxacin (up to 90%) was removed via adsorption when the pH was less 
than 5.5 in a laboratory experiment (Githinji et al. 2011). However, adsorption 
has been observed to decrease with increasing temperatures (Paus et al. 2014) 
and an increase in pH (pH > 6) (Githinji et al. 2011). In this study, the removal 
efficiency of ciprofloxacin occurred under a high ambient temperature (>26oC) 
and normal pH (7–8) conditions, which indicates that its removal appeared to be 
more as a result of biodegradation than adsorption.  
In summary, the high removal efficiencies of antibiotic compounds observed in 
this study may have occurred due to the high ambient temperatures and 
sunlight under the tropical climate conditions (in Saudi Arabia). This is because 
the high temperatures, in the range of 25 to 45°C, are likely to have promoted 
the growth rates and yields of the bacterial communities (LaPara et al. 2000).  
 
 Carbamazepine 
The removal efficiency of carbamazepine by WWTPs has previously been 
found to be poor (Clara et al. 2004; Mohapatra et al. 2012), mostly below 10% 
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(Zhang et al. 2008). Furthermore, an increase in carbamazepine concentrations 
after wastewater treatments has been reported (Joss et al. 2005; Vieno et al. 
2007) and was also observed in this study in relation to the UK MWWTPs 
(Table 5.2). In the treatment plants in Saudi Arabia as found in this study, a high 
average removal efficiency of carbamazepine (> 87%) at both HWWTPs was 
observed. The IHWWTP achieved 100% removal of the compound. In Malaysia, 
Dordio et al. (2009) has reported similar removal efficiencies in a constructed 
wetland (CW) in summer (97%), but at a lower level in winter (88%). The high 
ambient temperatures in Saudi Arabia may also have played a role in the higher 
removal efficiencies observed for carbamazepine. These findings were 
unexpected; they suggest that conventional WWTPs could remove 
carbamazepine under the right conditions and that tropical climate conditions 
are more favourable than temperate ones.  
 
 Atenolol  
The average removal efficiency of atenolol by the HWWTPs was 89%. The 
removal efficiencies of this compound reported in the literature vary drastically 
from study to study. For example, in WWTPs located in a temperate climate in 
Europe, Paxeus (2004) reported removal efficiencies of 10%, while Vieno et al. 
(2005) reported a removal efficiency of 61%. Castiglioni et al. (2006) found that 
the removal efficiency of atenolol was affected by temperature, where higher 
removal efficiencies were achieved in summer (55%) than in winter (10%). This 
indicates that the high removal efficiencies achieved by the HWWTPs in Saudi 
Arabia observed in this study could be due to higher microbial activity in a 
tropical climate. 
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 Lidocaine 
The average removal efficiency of lidocaine by the HWWTPs was 64%. The 
IHWWTP achieved 100% removal. The removal efficiency of lidocaine was 
tested in various WWTPs in a temperate climate (Hesse, Germany), where it 
was found to be significantly lower (10–50%) (Rúa-Gómez and Püttmann 2012) 
than that observed in this study. 
 
5.2.2.4 Discussion of the importance of key factors on removal 
efficiency 
The removal efficiencies of the pharmaceutical compounds measured in this 
study appeared to be much improved in the hotter, tropical climate of Saudi 
Arabia. The respective effects of key factors on the elimination of 
pharmaceuticals in the studied WWTPs are now discussed below: 
 
 Dilution factor  
The high dilution of raw sewage has been reported to reduce the removal 
efficiencies of pharmaceutical compounds during sewage treatment (Vieno et 
al. 2007). In this study, no dilution of the raw sewage had occurred (that is, the 
HWW was treated onsite, and not combined with rainwater, or other wastewater 
sources). Therefore, the higher removal efficiencies of the pharmaceutical 
compounds could also be attributed to a lack of dilution. For example, caffeine, 
paracetamol and ciprofloxacin were found in high concentrations in the influents 
to the HWWTPs, which probably then allowed higher removal rates. These 
results suggest that the lower the dilution factor of raw wastewater, the greater 
the removal efficiency. However, in the case of other compounds (e.g. 
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carbamazepine, atenolol, lidocaine and sulfamethoxazole) there were lower 
influent concentrations and yet higher removal efficiencies were still achieved. 
This indicates the possibility that other parameters, such as temperature, may 
affect the removal rates.  
 
 Temperature  
Higher removal efficiencies were observed during the summer in temperate 
climates, by an average of 25%, compared to winter (Vieno et al. 2005). In a 
previous study examining six large WWTPs in Italy, Castiglioni et al. (2006) also 
found higher removal efficiencies in summer (18.6°C) than in winter (9.7°C), 
except for carbamazepine and ciprofloxacin removal which were similar across 
the two seasons. In this study, 100% removal efficiencies in relation to 
carbamazepine and ciprofloxacin were achieved by the two HWWTPs. In 
addition, very high removal efficiencies with regard to antibiotics, atenolol and 
lidocaine were achieved; these compounds are normally found to be persistent 
at conventional WWTPs in temperate climates (Paxeus 2004; Rúa-Gómez and 
Püttmann 2012; Carballa et al. 2004). Thus, the higher ambient temperatures 
(>26°C) that are present almost year-round in the tropical Saudi Arabian climate 
may have enhanced the removal efficiencies of these compounds. The tropical 
conditions may have led to a high level of biological activity in the ASP, which 
may in turn have increased the biodegradation kinetics. Microorganisms living in 
reactors at WWTPs usually reach their optimal activity rates at warm 
temperatures, between 25–35°C (Cruikshank & Gilles 2007; Kareem 2013).  
Other factors, like nitrifying bacteria and sunlight availability (which is important 
in photodegradation) may also influence the removal efficiency of 
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pharmaceutical compounds (Kasprzyk-Hordern et al. 2009a). However, more 
comprehensive studies are needed to simultaneously investigate these factors 
and the potentially interrelated effects of temperature variation on the removal 
of pharmaceutical compounds during biological treatment processes.  
 
 Tertiary treatment  
HWWTPs applied tertiary treatment in the forms of sand filtration and 
disinfection.  It is possible that sand filtration had an effect on the efficiency of 
removal of the pharmaceutical compounds. However, the removal of 
pharmaceutical compounds during sand filtration has generally been reported to 
be inefficient (Hollender et al. 2009; Nakada et al. 2007). In this study, samples 
were collected from only raw sewage and final treated.  In the interpretation of 
the results reported in this study, it has been assumed that sand filtration and 
chlorination played a negligible role in the fate of the target micropollutants in 
the plants. Therefore, the contribution of both unit operations to the removal of 
pharmaceutical compounds requires investigation. 
 
5.3 Conclusion  
The removal efficiencies of pharmaceutical compounds were investigated in 
various biological treatment systems under different environmental conditions in 
a temperate climate (UK) and a tropical climate (Saudi Arabia). A summary of 
the removal efficiencies achieved is presented in Table 5.5 and ranges from no 
removal to very high removal (with the following categories; no elimination, poor 
<30%, moderate 30-70%, high 70-90% and very high > 90%). The degree of 
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removal efficiency of the pharmaceutical compounds appeared to strongly 
depend on the wastewater technology implemented in the WWTPs and the 
environmental conditions.  
 
Table 5.5: The average removal efficiencies of pharmaceutical compounds in 
temperate (UK) and tropical (Saudi Arabia) climates. 
Class Compound Temperate 
climate (UK) 
Tropical 
climate 
(SA) 
Analgesics & 
anti-
inflammatories 
Naproxen very high n/i 
Paracetamol very high very high 
 
Antidepressant 
 
Carbamazepine 
 
no elimination 
 
high 
 
β-blockers 
 
Lidocaine 
 
no elimination 
 
high 
 
Lipid 
 
Bezafibrate 
 
Moderate 
 
n/d 
 
Anaesthetics 
 
Atenolol 
 
moderate 
 
high 
 
Antibiotics 
 
Ciprofloxacin 
 
n/d 
 
very high 
Clarithromycin <LOQ high 
Sulfamethoxazol poor very high 
Metabolite of 
sulfamethoxazole 
NACS 
 
very high very high 
 
Others  
 
Caffeine 
 
n/i 
 
very high 
<LOQ= limit of quantitation; n/d= not detected; n/i=not included in the list 
 
In general, high removal efficiencies of up to 100% of analgesics, anti-
inflammatories and caffeine were achieved by most of the WWTPs, under both 
climatic conditions. Other compounds (carbamazepine and lidocaine) were not 
removed efficiently in the temperate climate, while high removal efficiencies 
were achieved in the tropical climate. Moderate removal efficiencies were 
achieved for bezafibrate and atenolol in the temperate climate, while high levels 
were achieved for atenolol in the tropical climate. Some of the antibiotic drugs 
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detected were not quantifiable in the UK WWTPs (except for sulfamethoxazole). 
This may be due to dilution effects or perhaps its consumption may be relatively 
low in the contributing catchment. In contrast, in the Saudi HWWTPs, antibiotic 
drugs were detected because hospitals are a point source for these compounds 
and there was low dilution of the HWW (on-site treatment and arid conditions). 
Very high removal efficiencies for most antibiotics, of up to 100%, were 
observed in the Saudi WWTPs.  
The observed removal efficiencies varied widely for the different compounds 
likely due to the different types of plant, operational differences (e.g. treatment, 
SRT, HRT, etc), temperature and dilution effects. Effective nitrification activities 
(which is usually associated with relatively high SRTs), in this study, have been 
positively correlated with increased HRT biodegradation rates of some 
compounds (e.g. naproxen, bezafibrate and atenolol). In tropical climate, with 
high ambient temperatures, sunlight and arid conditions, the WWTPs achieved 
even higher degrees of removal efficiencies (on average, 90%), for the most 
common compounds, including carbamazepine, lidocaine and sulfamethoxazole 
which in contrast, were found to be poorly degraded in the temperate climate.  
Overall, it can be hypothesized that longer SRT, HRT, an elevated ambient 
temperature, and dilution are the major factors that influence the removal 
efficiencies of pharmaceutical compounds. Ultimately, these conditions in ASP 
maximise the growth rate of microorganisms. However, it has to be emphasised 
that the removal efficiency of pharmaceutical compounds from wastewater 
during treatment does not necessarily indicate that they are fully degraded. 
Some compounds may only undergo partitioning from wastewater and be 
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adsorbed onto the sludge, without their complete mineralisation. Further 
treatment of the sludge may be then required in order to prevent the release of 
these compounds into the wider environment. 
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CHAPTER 6 
Assessment of the biodegradation of selected pharmaceutical 
compounds under aerobic and anaerobic conditions  
 
6.1 Introduction 
There are two main processes that act simultaneously to remove 
pharmaceutical compounds during biological treatment; biodegradation by 
bacterial communities and adsorption onto the sludge (Rattier et al. 2012). 
Biodegradation is the most important process involved in the removal of most 
pharmaceutical compounds during the biological treatment. The removal 
efficiencies of the pharmaceutical compounds vary from partial biodegradation 
to complete mineralisation; the degree of the elimination process depends on 
factors including the behaviour of the compounds, the solids retention time 
(SRT), hydraulic retention time (HRT), temperature and biomass concentration, 
among others (Chapter 5). Operational parameters like the SRTs and HRTs are 
important to consider when designing wastewater treatment plants (WWTPs), 
because they can be optimised to encourage the growth of microorganisms 
(Fernandez-Fontaina et al. 2012). The development of a complex species 
structure of biomass in a biological treatment system is expected to have an 
impact on the elimination of micropollutants. Clara et al. (2005a) identified a 
critical SRT of 10 days for activated sludge process for the removal of common 
macro-organic compounds, but there are inadequate data and the literature is 
lacking, on the relationship between the SRT and the removal of micropollutants 
during WWTP. In addition, pharmaceutical compounds in some WWTPs 
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systems and landfills will encounter anaerobic conditions. For example, 
compounds adsorbed onto solid sludge, produced from activated sludge 
processes, are commonly treated under anaerobic conditions for stabilisation 
and biogas production. This is how solid sludge from the Hatton MWWTP in the 
UK is treated. A drawback of the adsorption of pharmaceutical compounds onto 
solid sludge is that the compounds can later be released into the environment 
through the transport of sludge and its application in agriculture (Clarke and 
Smith 2011). Furthermore, where the wastewater has to travel long distances in 
sewers to the points of treatment, the wastewater can become septic due to 
anaerobic conditions within the sewerage system. This condition is more 
pronounced in tropical countries, due to relatively high ambient temperatures. 
Therefore, aerobic and anaerobic biodegradation experiments are necessary in 
order to gain an insight into the biodegradation behaviour of our target 
pharmaceuticals under these conditions. 
 
6.2. Materials and methods 
The materials and methods of the biodegradation experiments are reported in 
Chapter 3 (section 3.6). Briefly, short-term batch biodegradation tests were 
conducted for a subset of the target pharmaceutical compounds (paracetamol, 
naproxen, ibuprofen and sulfamethoxazole) from the WWTP experiments. High 
levels of these compounds have been reported in wastewater and receiving 
water samples (Roberts and Thomas 2006; Ashton et al. 2004; Thomas and 
Hilton 2004). The selection of these compounds was also based on:  
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1. Their general use; the pain killers paracetamol, naproxen and ibuprofen 
are commonly used drugs and can be bought over the counter.  
2. Earlier results from field studies (Chapter 5) showed paracetamol and 
naproxen to be present at high concentrations in the UK samples, and 
paracetamol to be present at high concentrations in the Saudi Arabia 
HWWTP samples. 
3. Antibiotics are used extensively by humans to treat microbial infections.  
Sulfamethoxazole was the only antibiotic detected in samples from both 
the UK and Saudi Arabian studies. Therefore, it was selected as a 
representative for antibiotics. 
4. Their potential impacts: there are relatively low PNECs for these 
compounds as reported in the literature review (Table 3.1). 
 
6.3 Results and discussion 
6.3.1 Aerobic biodegradation of selected compounds 
The aerobic batch tests were performed in duplicate. The experiments were run 
for 15 days until the first compound was almost completely removed (in this 
case, it was the culture containing paracetamol as shown in Figure 6.1). Only 
paracetamol showed high biodegradation efficiency, averaging 98% over 15 
days. At 10 days (the critical SRT time suggested by Clara et al. 2005a), the 
degradation efficiency of paracetamol was greater than 80%.  
Yu et al. (2006) also observed almost complete biodegradation of paracetamol 
at different initial concentrations (1 µg/L and 50 µg/L) in aerobic batch 
experiments following 14 days of incubation at room temperature (25°C). In 
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addition, in samples collected from the various WWTPs (as explained in 
Chapter 5), the concentrations of paracetamol were almost completely removed 
in the activated sludge plants. These results suggest that paracetamol can be 
regarded as relatively readily biodegradable under aerobic conditions and is 
therefore unlikely to persist during biological treatment processes. 
 
 
Fig. 6.1: Aerobic batch biodegradation of naproxen (Nap), ibuprofen (Ibu), 
sulfamethoxazole (Sufa) and paracetamol (Para) at various solid retention 
times. Results shown are mean ± standard deviation (n = 2); the vertical line 
represents a solids retention time of 10 days and allows comparison to the anaerobic 
digestion batch test. 
 
The biodegradation rates of ibuprofen and naproxen were, relative to 
paracetamol, low (Figure 6.1). Their concentrations only decreased by 30% and 
35% respectively over 15 days. Thus, the results suggest that ibuprofen and 
naproxen are not readily biodegradable. It can be seen from this figure that the 
degradation of naproxen started after a lag phase of about 5 days, after which 
point the concentrations of the compound started to decrease relatively quickly. 
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Grenni et al. (2013) also reported a lag phase, showing that the degradation of 
naproxen started after about 20 days. In the WWTPs study (Chapter 5), a high 
removal efficiency of naproxen was achieved at the nitrifying ASPs when a long 
aeration time was employed. Thus, the slow biodegradation of ibuprofen and 
naproxen in the batch tests study may be due to the bacteria present, which 
may not have adapted sufficiently to these pharmaceutical compounds during 
the experimental period. Additionally, there may have been limited adsorption of 
the compounds onto the culture biomass, since the solids contents of the 
culture bottles were relatively low. Nevertheless, adaptation of the bacterial 
biomass during WWTP processes has been identified as highly beneficial to 
compound biodegradation and this can be enhanced with longer SRTs in 
activated sludge (Falas et al. 2012; Petrie et al. 2014).  
There was no decrease in the concentration of sulfamethoxazole in the aerobic 
tests over the 15 day experimental period as shown in Figure 6.1. In addition, 
no significant influence of SRT was observed in the removal of 
sulfamethoxazole during the tests. Other studies have also shown that 
sulfamethoxazole is not readily biodegradable under aerobic conditions (Al-
Ahmad et al. 1999; Alexy et al. 2004; Gartiser et al. 2007). In addition, Larcher 
and Yargeau (2011) investigated the biodegradation of sulfamethoxazole by 
cultures of individual species of bacteria and a culture that included seven 
selected aerobic species of bacteria. The Rhodococcus equi culture resulted in 
29% removal of sulfamethoxazole, while the culture with seven species of 
bacteria only removed 5% of the compound (the initial sulfamethoxazole 
concentration was 6 mg/L). It has also been reported that aerobic biomass must 
be highly acclimated in order to efficiently remove sulfamethoxazole (Drillia et 
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al. 2005). The results of the aerobic tests support these conclusions and 
indicate that SRTs greater than 15 days may be required to improve 
biodegradation rates. 
 
6.3.2 Anaerobic biodegradation of selected compounds 
The biodegradation of the selected pharmaceutical compounds (paracetamol, 
naproxen, ibuprofen and sulfamethoxazole) under anaerobic conditions was 
assessed over 10 days until the first compound was almost completely removed 
(in this case, it was the culture containing sulfamethoxazole that showed more 
than 98% removal on Day 10 as shown in Figure 6.2). The elimination rate of 
sulfamethoxazole was consistent over the period. It is clear that 
sulfamethoxazole was biodegraded much faster under anaerobic conditions 
than in aerobic conditions (Figure 6.1). These results are consistent with those 
of Carballa et al. (2007) who found that the percentage removal of 
sulfamethoxazole under anaerobic conditions was about 98% over 10 days, at 
different initial concentration levels (4–400 µg/L). A field study also found that 
the biodegradation of sulfamethoxazole that occurred in anaerobic sludge 
removed more than 90% of the compound (Narumiya et al. 2013). Overall, the 
findings of this study support those of others and suggest that anaerobic 
conditions can efficiently eliminate sulfamethoxazole (and possibly other 
antibiotic compounds).  
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Fig. 6.2: Anaerobic batch biodegradation of naproxen (Nap), ibuprofen (Ibu), 
sulfamethoxazole (Sufa) and paracetamol (Para) at various solid retention 
times. Results shown are mean ± standard deviation (n = 2). 
 
 
Figure 6.2 also shows that paracetamol decreased by 80% over the 10-day 
period. It decreased by about 45% in the first two days and then by about 35% 
between days 2 and 10. Anaerobic treatment was previously found suitable to 
eliminate the majority of paracetamol, by more than 90% (De Graaff et al. 
2011); however, another study indicated that the removal efficiency of 
paracetamol in anaerobic digesters was only 11%, with a SRT of 56 days 
(Musson et al.  2010). An additional field study reported more than 80% 
biodegradation of paracetamol in anaerobic sludge (Narumiya et al. 2013). It 
appears from this study that paracetamol can be biodegraded by both aerobic 
and anaerobic microorganisms.  
The biodegradation of ibuprofen was less than 20% over the 10-day period 
(Figure 6.2); and biodegradation started after a lag phase of about 2 days. 
These results are in agreement with Carballa et al. (2007), who showed that the 
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removal efficiencies of ibuprofen varied between 40% and 60%, for various 
initial concentrations (4-400 µg/L) under anaerobic conditions during up to 30 
days incubation (or SRT). Also, Musson et al. (2010) showed overall reduction 
of ibuprofen of 28% under anaerobic conditions during 56 days experimentation 
for an initial concentration of 66 mg/L.   
The biodegradation characteristics of naproxen under anaerobic conditions in 
this study were similar to those of ibuprofen. The observed average removal 
efficiency of naproxen after 10 days was less than 25%. Recently, Alvarino et 
al. (2014) also reported a low removal efficiency of naproxen (< 15%) in an 
anaerobic digestion system. In contrast, Campbell (2013) reported a high 
removal efficiency of naproxen (up to 100%) under anaerobic digestion over a 
period of 60 days (with initial concentrations of 25 and 50 mg/L). Therefore, it is 
possible that the low removal efficiency of naproxen and ibuprofen under 
anaerobic conditions observed in this study may be due to the relatively short 
SRTs. A longer SRT will result in more biomass that will enhance the 
biodegradation rates and increase the methanogenic activity rates (Alvarino et 
al. 2014). 
 
6.3.3 Discussion of the biodegradation kinetics of selected 
compounds during biological treatment 
The observed biodegradation behaviours of the selected pharmaceutical 
compounds under aerobic and anaerobic conditions are shown in Table 6.1. 
Although different batch durations and concentrations of biomass were used for 
the both studies, the main aim of this work was to provide an examination into 
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the behaviour of the selected pharmaceuticals under different biological 
conditions and to compare the relative fate of the compounds under similar 
biological conditions. 
 
Table 6.1: Biodegradation rates of selected pharmaceuticals under aerobic and 
anaerobic conditions over 10 days. 
 
 
 
 
 
 
 
It is clear that sulfamethoxazole behaved completely differently under anaerobic 
versus aerobic conditions; while it was nearly completely removed under 
anaerobic conditions, poor biodegradation of the compound was observed 
under aerobic conditions, over 10 days. Previous studies have also shown 
efficient removal rates achieved by anaerobic digestion (Mohring et al. 2009; 
Larcher and Yargeau 2011). Antibiotics, especially fluoroquinolones and 
macrolides, have been shown to be less biodegradable in activated sludge 
plants (Baquero et al. 2008). However, high levels of removal under anaerobic 
conditions were observed for sulfamethoxazole and roxithromycin (Carballa et 
al. 2007), and oxytetracycline and chlortetracycline (Álvarez et al. 2010). 
Although, sulfamethoxazole was the only antibiotic assessed in this study, other 
antibiotics might behave similarly. Therefore, anaerobic conditions should be 
suitable to remove some these compounds. Providing anaerobic treatment as 
Compound Average rate of biodegradation 
 
 
Aerobic 
conditions 
Anaerobic 
conditions 
Paracetamol 80% 80% 
Ibuprofen 18% 20% 
Naproxen 18% 25% 
Sulfamethoxazole   3% 98% 
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part of wastewater treatment system may offer a cheaper alternative than 
installing advanced technologies (with or without activated sludge systems) 
especially in tropical climates, where high ambient temperature is available year 
round.   
Paracetamol appeared to be highly biodegradable under both aerobic and 
anaerobic conditions, with an average of 80% removal over 10 days (Table 6.1). 
In support of this, the results of the batch tests corroborate those from the 
effluent analysis of WWTPs in this study (Chapter 5), where the paracetamol 
present in the various WWTP influents from both the UK and Saudi Arabia was 
completely removed in the effluents. These findings suggest that, in general, 
paracetamol is a highly biodegradable compound under both aerobic and 
anaerobic biological treatment conditions. Consequently, if paracetamol was 
found to be present in the environment, it is expected that its concentrations 
would be relatively minimal and easily biodegradable by the microorganisms 
present in the surface waters. 
The biodegradation of naproxen and ibuprofen under both aerobic and 
anaerobic conditions were relatively similar (moderate). The similarities 
between naproxen and ibuprofen biodegradation profiles may be due to the fact 
that the microorganisms may require longer acclimation periods for their 
biodegradation. 
 
6.4 Conclusions 
The biodegradation of selected compounds in aerobic and anaerobic batch 
tests revealed different biodegradability potentials. Sulfamethoxazole was 
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completely biodegraded under anaerobic conditions, but poorly biodegraded 
under aerobic conditions. Incomplete and slow biodegradation of naproxen and 
ibuprofen under both aerobic and anaerobic conditions was probably due to the 
need for relatively longer microbial adaptation periods. Conversely, paracetamol 
concentrations were highly biodegradable under both aerobic and anaerobic 
conditions.  
Overall, on the basis of the biodegradation rates, the compounds can be divided 
into two groups. The first group (paracetamol) comprises pharmaceutical 
compounds that can be rapidly biodegraded under various environmental 
conditions. The second group (sulfamethoxazole, ibuprofen and naproxen) 
consists of those compounds that can be biodegraded, but only under certain 
conditions (e.g. longer SRT, HRT) or types of microorganisms. Where higher 
removal efficiencies of the pharmaceutical compounds were found, these could 
be explained by the different biomass and adaptation of the bacteria in the 
sludge over time. Therefore, the observations from the batch tests lead to the 
conclusion that combining anaerobic and aerobic biological treatment systems 
with longer SRTs could result in an overall increase in the removal efficiencies 
of pharmaceutical compounds.  
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CHAPTER 7 
Proposed pharmaceutical wastewater treatment for point 
sources 
7.1 Introduction 
In most cases, hospital wastewaters (HWWs) contain very high concentrations 
of pharmaceutical compounds and healthcare products. These compounds, 
along with other chemicals, are reportedly detected at higher concentrations in 
HWWs than in municipal wastewaters (as shown in Chapter 5). Separate 
treatment of HWW onsite can be designed to target the removal of specific 
pollutants at the point source. Removal efficiencies can thus be increased, 
however the costs of on-site treatment are significant. In some cases the 
installation of additional equipment will be required, and this will require 
operation and maintenance. This imposes associated costs, and may include a 
large energy requirement (Chapter 2; section 2.7). 
 
7.2 On-site treatment of hospital wastewater 
Hospital wastewaters have been shown to be a significant point source of 
pollutants contributing to the public sewer (Chapters 2 & 5). Consequently, the 
separation and treatment of concentrated wastewater at the point source (e.g. 
hospitals) represents an interesting option, as an alternative to centralised 
treatment. Such treatment would occur before dilution with other wastewater in 
the public treatment system so is likely to be more efficient. 
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7.3 Hospital wastewater separation at source 
Water is essential in all areas of hospitals and nursing homes. As reported in 
Chapter 2, the laundry, kitchen, air conditioning, heating and other sanitary 
facilities produce general wastewater that is not contaminated with 
pharmaceutical compounds. In contrast, other units, such as laboratories, 
patients’ wards, intensive care and other medical service units, produce 
hazardous wastewater. Within hospital sewers, both hazardous and 
unhazardous wastewaters are mixed. However, because the units that generate 
hazardous wastewater are known, the non-hazardous wastewater units 
(laundry, kitchen etc.) could be directly connected to urban sewerage systems, 
whilst the wastewater stream containing hazardous pollutants could undergo 
onsite treatment. In this arrangement, better control and efficient treatment of 
pharmaceutical compounds, would be possible. Pharmaceutical compounds of 
concern would be present at higher concentrations in the wastewater stream 
directed to the onsite treatment system as they would not be diluted with 
general, non-hazardous wastewater.  
 
7.4 Proposed treatment processes for pharmaceutical compounds 
Worldwide, hospital and municipal wastewater treatment plants (WWTPs) 
commonly employ aerobic activated sludge processes. As shown in Chapters 5 
and 6, the pharmaceutical compounds investigated in this research were 
affected by treatment processes under both aerobic and anaerobic conditions. 
In a conventional activated sludge process, the biodegradation rates of 
pharmaceutical compounds appeared higher under certain operational 
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conditions, including long SRTs and HRTs, lower levels of dilution and higher 
ambient temperatures. Therefore, on-site treatment and upgrading an activated 
sludge process to optimize the conditions could significantly increase the 
removal efficiencies of pharmaceutical compounds. Due to the different climatic 
conditions, which affect the ambient temperature, different options are proposed 
for the point source treatment of pharmaceutical compounds under tropical and 
temperate climates.  
 
7.4.1 Tropical climate  
Many of the world's regions are subject to warm climatic conditions particularly 
developing countries (Baruselli et al. 2004). A warm climate is favourable for 
biological treatment with bacteria, because the elevated temperatures play an 
important role in bacterial growth and activity during treatment (Risk and Baath 
2011; Nydahl et al. 2013; Yang et al. 2014). Based on the results of this 
research, the integration of an anaerobic and aerobic biological treatment stage 
as shown in Figure 7.1 is proposed, along with longer SRTs and HRTs that will 
enhance the overall efficiency of biodegradation of pharmaceutical compounds.  
 
 
Fig. 7.1: The proposed treatment of pharmaceutical compounds under elevated 
temperatures (in tropical climates). 
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With the digestion processes maintained at ambient temperatures, anaerobic 
digestion is proposed as a pre-treatment (at an ambient temperature) and the 
aerobic treatment conditions would comprise a post-treatment, with optimised 
SRT and HRT. The anaerobic conditions would be important for the reduction of 
pharmaceuticals, especially antibiotics, and the aerobic conditions would reduce 
other pharmaceuticals and remaining organic pollutants. For existing activated 
sludge plants, upgrading to ensure longer HRTs (and also ensuring that the 
SRT is between 10-15 days), and using complete nitrification as an indicator is 
recommended. The combination of aerobic and anaerobic processes would 
enhance the overall efficiency of biodegradation of the pharmaceutical 
compounds. This process would have the additional advantage of increasing 
the removal efficiency of ammonia and would be more cost-effective than 
adding advanced treatment process units. Anaerobic–aerobic treatment has 
numerous advantages, such as low energy consumption, low chemical 
consumption, low sludge production, less equipment required and operational 
simplicity (Chan et al. 2009). In addition, for high strength wastewater, the 
anaerobic zone could produce methane gas and this biogas could be captured 
to produce renewable energy.  
 
7.4.2 Temperate climate 
The treatment of pharmaceutical compounds in wastewater under low ambient 
temperature conditions may only lead to limited biodegradation of the pollutants 
under anaerobic digestion (Bowen et al. 2014; Zeman et al. 2014). Therefore, in 
temperate climates it is likely that the anaerobic treatment process would need 
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to be heated to above 30°C to optimise biodegradation rates. However, heating 
of the anaerobic zone during treatment could be costly. Therefore, as an 
alternative, advanced treatment processes could be used and are proposed for 
use in temperate climates as shown in Figure 7.2. 
 
 
Fig. 7.2: The proposed treatment of pharmaceutical compounds under low 
temperatures (in temperate climates). 
 
 
From the results obtained in this study of the performance of some  WWTPs in 
the UK, upgrading activated sludge processes to a total SRT of 15 days or more 
with a longer HRT (>15 hours)  is recommended. When the SRT in the aeration 
tank is sufficiently long, the removal of pharmaceutical compounds during the 
aerobic treatment process may be enhanced. An extended aeration system is 
likely to ensure the effective adaptation of microbial communities to the micro-
organic pollutants in the aeration tank. Alternatively, extended aeration and 
longer SRTs can be obtained by the use of membrane bioreactors (MBRs). 
MBRs also have the advantage of eliminating the use of a secondary 
sedimentation tank for biomass-treated effluent separation (Akunna and Bartie 
2014), thereby making it ideal for use where space is limited. 
Pharmaceutical compounds, such as carbamazepine, that are resistant or 
recalcitrant to microbial degradation under sub-optimal temperature conditions 
(i.e., in a temperate climate), can be treated with an additional advanced 
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treatment such as activated carbon. Activated carbon is recommended to 
reduce the emissions of these compounds into the environment. Although 
activated carbon can be costly, the amount used depends on the concentrations 
of the compounds released from the secondary (activated sludge) treatment. It 
is expected that the amount of activated carbon used will be affordable if used 
as a post-treatment step, where an extended aeration system, as proposed in 
Figure 7.2, is optimised to remove most of the readily and non-readily 
biodegradable compounds prior to post-treatment. 
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CHAPTER 8 
General conclusions 
The aim of this thesis was to contribute to the knowledge concerning the 
occurrence and behaviour of pharmaceutical compounds during municipal and 
hospital wastewater treatment under different environmental conditions. The 
main conclusions and results obtained from this research are summarised 
below. 
 
8.1 The occurrence of pharmaceutical compounds in municipal and 
hospital wastewaters  
Samples from the influent and effluent of conventional municipal and hospital 
wastewater treatment plants in the UK and Saudi Arabia were analysed to 
investigate the occurrence and elimination of selected pharmaceutical 
compounds. The highest concentrations of pharmaceutical compounds 
measured in the influents of municipal WWTPs (> 1 µg/L) were of paracetamol, 
naproxen and bezafibrate, followed by carbamazepine, atenolol, lidocaine, 
sulfamethoxazole and NACS, the concentrations of which were less than 1 
µg/L. In the hospital WWTPs, the highest concentrations of pharmaceutical 
compounds measured (> 10 µg/L) were of paracetamol and caffeine, followed 
by ciprofloxacin and NACS (1–6 µg/L), and finally bezafibrate, carbamazepine, 
atenolol, lidocaine, clarithromycin and sulfamethoxazole (< 1 µg/L). In general, 
the hospital wastewater contained relatively higher levels of the pharmaceutical 
compounds measured than the municipal wastewater. Various antibiotics were 
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frequently detected in the hospital wastewater, while only one type of antibiotic 
was detected in the municipal wastewater.  
 
8.2 The effect of operational parameters on the removal efficiency of 
pharmaceutical compounds in wastewater treatment plants 
8.2.1 Solids retention time and hydraulic retention time 
Higher removal efficiencies of paracetamol, naproxen, bezafibrate and atenolol 
were achieved in activated sludge processes operating with longer hydraulic 
retention times (HRTs > 15 h) and solids retention times (> 10 days, as 
indicated by the occurrence of effective nitrification) than those with shorter 
HRTs and SRTs in the UK WWTPs. A longer SRT seemed to promote the 
adaptation of different kinds of microorganisms, including slow growing species 
that could have a greater capacity for removing the compounds of interest.  
 
8.2.2 Ambient temperature  
In terms of the pharmaceutical compounds investigated, greater removal 
efficiencies were achieved for atenolol, carbamazepine, lidocaine and 
antibiotics in an activated sludge plant in a tropical climate. These compounds 
are normally found to be persistent at conventional WWTPs in temperate 
climates. The higher ambient temperatures (> 26°C), which are present almost 
year-round in the tropical climate, could bring about higher levels of microbial 
activity and ensure increased biodegradation kinetics of organic pollutants in the 
wastewater.  
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8.2.3 Dilution factor  
Where hospital wastewater is co-treated with municipal wastewater, as in the 
UK, high volumes of municipal wastewater may dilute the overall concentrations 
of the pharmaceutical compounds in the combined wastewater. Similarly, 
rainfall reaching the combined system can also contribute to dilution of the 
concentrations of pharmaceuticals present in the wastewater. In this study, it 
was found that the removal efficiencies of pharmaceutical compounds were 
considerably greater in the dry tropical conditions in Saudi Arabia than in wet 
weather conditions in the UK, even though the concentrations of these 
compounds in the UK wastewater were lower. This may be due to the effect of 
dilution, although more research is needed to draw explicit conclusions. Even 
though poor removal rates were achieved during wet weather conditions, the 
effects of dilution would have also reduced the possible environmental hazards 
posed by the compounds to aquatic organisms. 
 
8.3 The effect of anaerobic and aerobic biodegradation   
In order to compare biodegradation rates under aerobic and anaerobic 
conditions, laboratory biodegradation experiments were conducted. Aerobic and 
anaerobic digestion processes were operated for extended periods in the 
laboratory and the biodegradation rates of four pharmaceutical compounds 
were measured. The biodegradation rates varied significantly ranging from poor 
to high depending on the retention period considered. High levels of 
paracetamol were removed (> 90%) during both the aerobic and anaerobic 
conditions. Ibuprofen and naproxen elimination rates were moderate under both 
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aerobic and anaerobic conditions, while the elimination of sulfamethoxazole 
was poor under aerobic and high under anaerobic conditions. The most relevant 
impact on the removal of the compounds was the SRT and the type of 
microorganisms used (i.e. aerobic vs. anaerobic). A longer SRT enhanced the 
adaptation of microorganisms and increased the microbial activity, which 
improved the removal efficiencies of the pharmaceutical compounds. The 
results thus confirmed observations from the treatment plant studies. 
 
8.4 Proposed treatment processes for pharmaceutical compounds 
The proposed treatment process recommends the separation of hospital 
wastewater. Under tropical conditions, combining aerobic and anaerobic 
treatment with longer SRTs (10-15 days) and HRTs (> 10 h) is recommended to 
enhance the overall biodegradation efficiency of most readily and non-readily 
biodegradable pharmaceutical compounds in municipal and hospital 
wastewaters. Advanced processes, can be added as post-treatment to remove 
compounds that are resistant or recalcitrant to microbial degradation in 
temperate conditions.        
 
8.5 Recommendations for future research 
The knowledge about the fate and behaviour of pharmaceutical compounds in 
wastewater gathered from this work confirms that the degree of biodegradation 
of pharmaceutical compounds in conventional activated sludge systems 
depends on factors, such as the type of process (aerobic or anaerobic), SRT 
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and temperature. Based on these results and the conclusions of this work, the 
following recommendations for further research can be made: 
 In this research, parent compounds and their metabolites were detected 
in the collected samples. However, only the parent compounds were 
analysed, except for the metabolites of sulfamethoxazole (NACS). More 
research is therefore needed in order to understand the fate of the 
produced metabolites and their biodegradability.  
 It is necessary to investigate the impacts of long-term exposure of 
microorganisms to pharmaceutical compounds in water systems, along 
with the wider environmental risks.  
 The analysis of pharmaceutical compounds at low concentrations 
currently presents a challenge. More research is recommended to 
improve the accuracy and ease of analysis of pharmaceutical 
compounds. 
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UK Sampling data 
BOD5 (mg/L) 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
18/09/12 
19/09/12 
26/09/12 
03/10/12 
05/10/12 
10/10/12 
12/10/12 
17/10/12 
18/10/12 
23/10/12 
24/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Letham 
 
34.53 
38.41 
22.07 
52.46 
-- 
74.12 
-- 
32.21 
-- 
-- 
-- 
-- 
-- 
43.00 
61.87 
4.37 
4.68 
5.36 
12.78 
6.85 
8.03 
10.98 
6.59 
6.25 
6.52 
7.67 
6.04 
5.93 
8.82 
7.52 
 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
18/09/12 
19/09/12 
26/09/12 
03/10/12 
05/10/12 
10/10/12 
12/10/12 
17/10/12 
18/10/12 
23/10/12 
24/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Cupar  
 
156.26 
181.96 
130.24 
201.80 
-- 
225.92 
-- 
144.30 
-- 
-- 
-- 
-- 
-- 
229.60 
256.76 
2.16 
0.28 
2.52 
9.17 
8.67 
7.45 
13.87 
6.49 
4.76 
3.74 
5.75 
3.59 
5.44 
4.13 
3.93 
 
No.   Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
18/09/12 
19/09/12 
26/09/12 
03/10/12 
05/10/12 
10/10/12 
12/10/12 
17/10/12 
18/10/12 
23/10/12 
24/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Guardbridge 
 
33.61 
72.51 
42.42 
62.14 
-- 
105.56 
-- 
56.76 
-- 
-- 
-- 
-- 
-- 
58.40 
87.75 
5.83 
3.03 
9.13 
7.76 
7.73 
7.16 
9.74 
4.98 
8.05 
3.57 
5.07 
1.86 
5.93 
4.69 
2.89 
 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
03/10/12 
10/10/12 
12/10/12 
15/10/12 
18/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Hatton  
 
25.95 
64.10 
89.71 
48.40 
-- 
-- 
-- 
34.96 
61.84 
1.55 
0.42 
5.17 
7.52 
4.36 
3.66 
5.81 
4.10 
3.52 
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COD (mg/L) 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
18/09/12 
19/09/12 
26/09/12 
03/10/12 
05/10/12 
10/10/12 
12/10/12 
17/10/12 
18/10/12 
23/10/12 
24/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Letham 
 
175 
132 
70.2 
101 
-- 
158 
-- 
61.4 
-- 
-- 
-- 
109 
-- 
104 
145 
33.4 
29.6 
31.4 
32.7 
28.1 
34.1 
29.7 
21.8 
23.5 
30.7 
20.2 
34.3 
21.2 
37.2 
39.8 
 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
18/09/12 
19/09/12 
26/09/12 
03/10/12 
05/10/12 
10/10/12 
12/10/12 
17/10/12 
18/10/12 
23/10/12 
24/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Cupar  
 
470 
491 
354 
344 
-- 
464 
-- 
233 
-- 
-- 
-- 
317 
-- 
487 
607 
22.4 
20.5 
26.7 
24.1 
35.9 
28.0 
26.9 
22.1 
21.8 
19.1 
17.0 
17.0 
18.3 
15.9 
22.7 
 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
 15 
18/09/12 
19/09/12 
26/09/12 
03/10/12 
05/10/12 
10/10/12 
12/10/12 
17/10/12 
18/10/12 
23/10/12 
24/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Guardbridge 
 
136 
182 
130 
109 
-- 
232 
-- 
143 
-- 
-- 
-- 
91.6 
-- 
123 
199 
13.6 
16.5 
39.4 
19.1 
18.3 
18.3 
22.9 
18.2 
24.0 
13.5 
17.5 
16.0 
18.6 
15.2 
20.8 
 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
03/10/12 
10/10/12 
12/10/12 
15/10/12 
18/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Hatton  
 
78.5 
177 
119 
68.6 
-- 
157 
81.7 
81.7 
142 
22.0 
20.7 
18.2 
23.6 
16.8 
19.8 
24.4 
28.6 
26.3 
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TOC (mg/L) 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
18/09/12 
19/09/12 
26/09/12 
03/10/12 
05/10/12 
10/10/12 
12/10/12 
17/10/12 
18/10/12 
23/10/12 
24/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Letham 
 
45.8 
59.2 
30.1 
38.7 
-- 
65.3 
-- 
29.6 
-- 
-- 
-- 
43.9 
-- 
44.4 
37.4 
9.73 
11.7 
10.8 
6.39 
10.1 
11.4 
8.13 
7.33 
6.88 
12.0 
4.81 
15.3 
4.65 
12.0 
13.8 
 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
18/09/12 
19/09/12 
26/09/12 
03/10/12 
05/10/12 
10/10/12 
12/10/12 
17/10/12 
18/10/12 
23/10/12 
24/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Cupar  
 
137 
225 
117 
110 
-- 
145 
-- 
61.9 
-- 
-- 
-- 
110 
-- 
126 
181 
7.19 
9.46 
2.97 
2.58 
6.48 
9.85 
7.31 
5.08 
7.52 
6.82 
8.34 
6.96 
7.65 
5.82 
8.12 
 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
18/09/12 
19/09/12 
26/09/12 
03/10/12 
05/10/12 
10/10/12 
12/10/12 
17/10/12 
18/10/12 
23/10/12 
24/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Guardbridge 
 
41.0 
71.4 
42.5 
53.5 
-- 
105 
-- 
56.6 
-- 
-- 
-- 
28.8 
-- 
35.3 
35.1 
9.48 
9.00 
7.09 
3.19 
3.99 
2.89 
4.90 
2.96 
6.61 
3.70 
7.50 
5.84 
4.12 
5.69 
6.45 
 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
03/10/12 
10/10/12 
12/10/12 
15/10/12 
18/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Hatton 
 
37.3 
57.4 
44.4 
50.8 
-- 
91.1 
-- 
43.1 
53.8 
9.07 
8.83 
10.5 
7.59 
6.19 
5.90 
4.14 
10.2 
5.47 
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NH4 (mg/L) 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
18/09/12 
19/09/12 
26/09/12 
03/10/12 
05/10/12 
10/10/12 
12/10/12 
17/10/12 
18/10/12 
23/10/12 
24/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Letham 
 
15.2 
16.9 
3.02 
7.96 
-- 
16.4 
-- 
3.60 
-- 
-- 
 
5.35 
-- 
13.7 
19.7 
1.56 
1.23 
0.32 
0.55 
0.00 
 0.99 
0.00 
0.00 
0.00 
0.24 
0.20 
1.72 
0.72 
1.69 
1.38 
 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
18/09/12 
19/09/12 
26/09/12 
03/10/12 
05/10/12 
10/10/12 
12/10/12 
17/10/12 
18/10/12 
23/10/12 
24/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Cupar  
 
22.0 
47.5 
11.8 
17.7 
-- 
34.6 
-- 
18.6 
-- 
-- 
-- 
20.4 
-- 
21.0 
25.1 
0.99 
1.60 
0.13 
0.49 
0.00 
0.00 
0.00 
0.00 
0.00 
0.05 
0.04 
0.05 
0.46 
0.075 
0.134 
 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
18/09/12 
19/09/12 
26/09/12 
03/10/12 
05/10/12 
10/10/12 
12/10/12 
17/10/12 
18/10/12 
23/10/12 
24/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Guardbridge 
 
18.9 
31.4 
11.5 
13.6 
-- 
39.1 
-- 
15.8 
-- 
-- 
-- 
13.6 
-- 
14.6 
31.0 
0.13 
0.00 
0.00 
0.05 
0.00 
0.00 
0.00 
0.02 
0.00 
0.06 
0.03 
0.05 
0.21 
0.095 
0.569 
 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
03/10/12 
10/10/12 
12/10/12 
15/10/12 
18/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Hatton  
 
22.1 
32.5 
11.2 
15.6 
-- 
24.6 
-- 
18.5 
27.9 
23.9 
30.2 
12.7 
18.1 
8.40 
17.6 
16.3 
22.7 
19.9 
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NO3 (mg/L) 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
18/09/12 
19/09/12 
26/09/12 
03/10/12 
05/10/12 
10/10/12 
12/10/12 
17/10/12 
18/10/12 
23/10/12 
24/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Letham 
 
0.00 
0.00 
18.7 
11.5 
-- 
14.8 
-- 
24.9 
-- 
-- 
-- 
15.5 
-- 
12.8 
16.1 
54.7 
63.5 
  34.5 
54.1 
47.6 
72.6 
19.7 
44.2 
36.6 
35.5 
44.1 
79.0 
54.7 
67.2 
63.2 
 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
18/09/12 
19/09/12 
26/09/12 
03/10/12 
05/10/12 
10/10/12 
12/10/12 
17/10/12 
18/10/12 
23/10/12 
24/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Cupar  
 
0.00 
0.00 
7.84 
5.36 
-- 
5.32 
-- 
15.6 
-- 
-- 
-- 
0.00 
-- 
1.45 
7.28 
25.3 
23.3 
24.4 
31.7 
28.1 
40.4 
17.7 
38.3 
32.3 
45.5 
42.3 
42.5 
37.5 
41.7 
33.7 
 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
18/09/12 
19/09/12 
26/09/12 
03/10/12 
05/10/12 
10/10/12 
12/10/12 
17/10/12 
18/10/12 
23/10/12 
24/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Guardbridge 
 
0.51 
0.00 
12.9 
17.5 
-- 
4.46 
-- 
20.2 
-- 
-- 
-- 
11.9 
-- 
7.16 
7.33 
66.1 
51.8 
47.7 
74.7 
70.9 
75.4 
25.9 
52.6 
31.2 
67.1 
61.5 
74.8 
62.7 
75.5 
71.6 
 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
03/10/12 
10/10/12 
12/10/12 
15/10/13 
18/10/12 
30/10/12 
01/11/12 
06/11/12 
09/11/12 
Hatton  
 
1.39 
0 
5.16 
3.52 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
1.94 
0.00 
0.00 
0.00 
7.68 
0.00 
0.00 
0.00 
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Saudi sampling data 
COD (mg/l) 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
02/04/14 
04/04/14 
07/04/14 
10/04/14 
15/04/14 
18/04/14 
23/04/14 
28/04/14 
IHWWTP 
 
348 
317 
344 
  - 
321 
349 
- 
339 
25 
26 
30 
- 
24 
28 
 
26 
 
 
NH4 (mg/l) 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
02/04/14 
04/04/14 
07/04/14 
10/04/14 
15/04/14 
18/04/14 
23/04/14 
28/04/14 
IHWWTP 
 
16.2 
13.1 
27.6 
 
12.6 
23.5 
- 
20.9 
0.0 
0.0 
0.0 
 
0.0 
0.0 
- 
0.0 
 
 
NO2 (mg/l) 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
02/04/14 
04/04/14 
07/04/14 
10/04/14 
15/04/14 
18/04/14 
23/04/14 
28/04/14 
IHWWTP 
 
0.70 
0.34 
0.02 
- 
0.35 
0.31 
- 
0.28 
0.29 
0.3 
0.0 
- 
0.39 
0.25 
- 
0.26 
 
 
NO3 (mg/l) 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
02/04/14 
04/04/14 
07/04/14 
10/04/14 
15/04/14 
18/04/14 
23/04/14 
28/04/14 
IHWWTP 
 
0.43 
0.33 
0.32 
- 
0.32 
0.29 
- 
0.39 
2.49 
3.1 
1.54 
- 
2.13 
3.12 
- 
2.44 
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Saudi sampling data 
COD (mg/l) 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
02/04/14 
04/04/14 
07/04/14 
10/04/14 
15/04/14 
18/04/14 
23/04/14 
28/04/14 
SHWWTP 
 
476 
294 
358 
- 
350 
406 
- 
371 
74 
58 
66 
- 
56 
69 
- 
58 
 
 
NH4   (mg/l) 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
02/04/14 
04/04/14 
07/04/14 
10/04/14 
15/04/14 
18/04/14 
23/04/14 
28/04/14 
SHWWTP 
 
14.25 
32.50 
23.58 
- 
18.9 
26.10 
- 
19.00 
0.00 
0.24 
0.38 
- 
0.31 
0.31 
- 
0.29 
 
 
NO2  (mg/l) 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
02/04/14 
04/04/14 
07/04/14 
10/04/14 
15/04/14 
18/04/14 
23/04/14 
28/04/14 
SHWWTP 
 
0.39 
0.36 
0.10 
- 
0.41 
0.31 
- 
0.26 
1.01 
0.55 
0.07 
- 
0.73 
0.63 
- 
0.69 
 
 
NO3   (mg/l) 
No.  Date  Plant Influent Effluent 
1 
2 
3 
4 
5 
6 
7 
8 
02/04/14 
04/04/14 
07/04/14 
10/04/14 
15/04/14 
18/04/14 
23/04/14 
28/04/14 
SHWWTP 
 
0.12 
0.14 
0.34 
- 
0.3 
0.29 
- 
0.19 
0.90 
0.62 
0.51 
- 
0.66 
0.70 
- 
0.61 
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Sampling for measurement of pharmaceutical compounds 
 
 
 
 
 
No.  Date  Time   UK Plants  
Hatton Cupar  Guardbridge  Letham  
1 03/10/12 9:00-14:00         
2 05/10/12 9:00-14:00 -       
3 10/10/12 9:00-14:00         
4 12/10/12 9:00-14:00         
5 15/10/12 10:00   - - - 
6 17/10/12 9:00-14:00 -       
7 18/10/12 9:00-14:00         
8 01/11/13 11:00   - - - 
9 06/11/12 9:00-14:00         
10 09/11/12 9:00-14:00         
11 3/6/2013 9:00-14:00         
12 06/06/13 9:00-14:00         
13 11/06/13 9:00-14:00         
14 14/06/13 9:00-14:00         
15 18/06/13 9:00-14:00         
16 21/06/13 9:00-14:00         
17 25/06/13 9:00-14:00         
18 28/06/13 9:00-14:00         
   Saudi Arabia plants  
Salman hospital Iman hospital 
19 02/04/14 11:00-14:00     
21 04/04/14 11:00-14:00     
22 07/04/14 11:00-14:00     
23 10/04/14 11:00-14:00     
24 15/04/14 11:00-14:00     
25 18/04/14 11:00-14:00     
26 23/04/14 11:00-14:00     
27 28/04/14 11:00-14:00     
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UK sample analysis 
 
UK samples were analysed by LC-MS/MS (Agilent 1100 series LC system, 
auto-sampler). 
HPLC conditions: 
Column:  Atlantis dC18 3um 2.1 x 150mm  
Mobile Phase A:  acetonitrile 
Mobile Phase B:  ammonium formate (10 mM)/formic acid/water (pH 3.5) 
Time: 0-45 min  
 
Analyte  Precursor  
Product 
ion 
Amplitude  
Retention 
time 
(min) 
Mode  
Atenolol  267.1 190.0 0.45 10 Positive  
Iopamodol  778.0 614.7 0.50 2.8 Positive 
Ioprimide  791.8 773.0 0.50 2.7 Positive 
Lidocaine  235.1 773.8 0.50 2.7 Positive 
Ciprofloxacin 331.9 288.3 0.90 12.8 Positive 
Cyclophosphamide  261.0 139.9 0.45 16.5 Positive 
Sulfamethoxazole  254.0 155.9 0.40 15.8 Positive 
Ifosfamide 261.0 155.9 0.40 15.8 Positive 
NASC 296.0 136.0 0.60 16.6 Positive 
Carbamazepine  237.0 194.0 0.60 25.6 Positive 
Clarithromycin  748.4 590.3 0.30 30.8 Positive 
Bezafibrate  362.1 316.0 0.45 32 Positive 
Naproxen  231.0 185.0 0.50 32 Positive 
Ibuprofen  204.8 160.8 0.70 34.9 Negative  
 
Precursor and product ions showing the amplitude for fragmentation and 
retention time. Nebuliser Gas 40 psi, Dry Gas 7l/min and Dry Temp was 340oC. 
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Calibration Curve for carbamazepine 
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Chromatogram for carbamazepine in SRM mode and the product ion scan 
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Saudi samples analysis 
 
Saudi samples were analysed by LC-MS/MS (Thermo Scientific Q Exactive 
Quadrupole-Orbitrap Mass Spectrometer). 
HPLC conditions: 
Column:  Waters Xselect HSS T3. 2.1 x 150 mm (30 ± 2°C) 
Mobile Phase A:  acetonitrile 
Mobile Phase B:  ammonium formate (10 mM)/formic acid/water (pH 3.5) 
Times: 0-33 min 
Time (min) A% B% 
Flow rate 
(ml/min) 
0.00 1 99 0.2 
2.00 1 99 0.2 
5.00 30 70 0.2 
15.00 30 70 0.2 
20.00 99 1 0.2 
25.00 99 1 0.2 
26.00 1 99 0.2 
33.00 1 99 0.2 
 
 
Mass spectrometry: positive ion mode. 
Analyte MS ion/transition MS experiment 
Atenolol 267.1703 full scan 
Bezafibrate 362.11-316.1089 targeted MS2 
Carbamazepine 237.10-194.0964 targeted MS2 
Caffeine 195.0877 full scan 
Ciprofloxacin 332.14-288.1505 targeted MS2 
Clarithromycin 748.48-158.1176 targeted MS2 
Cyclophosphamide 261.03-140.0029 targeted MS2 
Erythromycin 734.47-158.1176 targeted MS2 
Lidocaine 235.1805 full scan 
NACS 296.07-134.0602 targeted MS2 
Paracetamol 152.0706 full scan 
Sulphamethoxazole 254.06-108.0445 targeted MS2 
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Calibration Curve and chromatogram for paracetamol 
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Calibration Curve and chromatogram for clarithromycin 
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Calibration curve and chromatogram for cyclophosphamide  
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Calibration curve and chromatogram for erythromycin 
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Calibration curve and chromatogram for NACS  
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Calibration curve and chromatogram for lidocaine 
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Calibration curve and chromatogram for Sulfamethoxazole 
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Calibration curve and chromatogram for caffeine 
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Calibration curve and chromatogram for atenolol 
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Calibration curve and chromatogram for bezafibrate 
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Calibration curve and chromatogram for carbamazepine 
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Calibration curve and chromatogram for ciprofloxacin 
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Decreasing concentrations of selected pharmaceuticals in aerobic and anaerobic 
batches 
 
  
Value expressed as % peak area of T0 
 
  
Sample Naproxen Ibuprofen Sulphamethoxazole Paracetamol 
 
Hamed1 Mix-0A SRT MIXWO0asrt 100.00 100.00 100.00 100.00 
Aerobic 
digestion 
Hamed2 Mix-1A SRT MIXWO1asrt 100.00 98.23 100.00 87.21 
Hamed3 Mix-2A SRT MIXWO2asrt 99.00 93.49 98.01 67.41 
Hamed4 Mix-5A SRT MIXWO5asrt 95.66 89.66 94.23 44.56 
Hamed5 Mix-8A SRT MIXWO8asrt 88.16 84.50 94.00 30.77 
Hamed6 Mix-11A SRT MIXWO11asrt 76.92 79.12 94.89 10.90 
Hamed7 Mix-15A SRT MIXWO15asrt 68.16 66.58 93.10 0.00 
Hamed8 Mix-0B SRT MIXWO0bsrt 100.00 100.00 100.00 100.00 
Hamed9 Mix-1B SRT MIXWO1bsrt 99.00 97.92 99.23 91.09 
Hamed10 Mix-2B SRT MIXWO2bsrt 98.19 97.56 99.20 75.13 
Hamed11 Mix-5B SRT MIXWO5bsrt 97.00 94.51 98.26 54.79 
Hamed12 Mix-8B SRT MIXWO8bsrt 92.04 86.33 97.32 35.96 
Hamed13 Mix-11B SRT MIXWO11bsrt 79.23 79.01 96.59 17.26 
Hamed14 Mix-15B SRT MIXWO15bsrt 63.92 73.29 96.00 4.47 
Hamed15 AD B1-0 SRT AD B1 OD 100.00 100.00 100.00 100.00 
Anaerobic 
digestion 
Hamed16 AD B1-2 SRT AD B1 2D 91.16 98.01 59.73 49.16 
Hamed17 AD B1-4 SRT AD B1 4D 90.01 88.01 33.23 40.09 
Hamed18 AD B1-6 SRT AD B1 6D 87.16 83.20 17.09 33.64 
Hamed19 AD B1-8 SRT AD B1 8D 77.83 81.38 5.45 26.50 
Hamed20 AD B1-10 SRT AD B1 1OD 74.17 80.13 0.00 18.00 
Hamed21 
Hamed22 
AD B2-0 SRT AD B2 OD 100.00 100.00 100.00 100.00 
AD B2-2 SRT AD B2 2D 87.03 100.00 75.21 63.91 
Hamed23 AD B2-4 SRT AD B2 4D 87.88 90.97 43.59 51.25 
Hamed24 AD B2-6 SRT AD B2 6D 85.05 88.79 21.04 46.06 
Hamed25 AD B2-8 SRT AD B2 8D 81.64 84.00 10.42 33.50 
Hamed26 AD B2-10 SRT AD B2 10D 77.00 79.61 3.30 23.05 
 
 
